

MIT Open Access Articles

Ribosome Levels Selectively Regulate Translation and Lineage Commitment in Human Hematopoiesis

The MIT Faculty has made this article openly available. **Please share** how this access benefits you. Your story matters.

Citation: Khajuria, Rajiv K, et al. "Ribosome Levels Selectively Regulate Translation and Lineage Commitment in Human Hematopoiesis." *Cell* 173, 1 (March 2018): 90–103 © 2018 Elsevier Inc.

As Published: <http://dx.doi.org/10.1103/10.1016/j.cell.2018.02.036>

Publisher: Elsevier BV

Persistent URL: <https://hdl.handle.net/1721.1/122812>

Version: Author's final manuscript: final author's manuscript post peer review, without publisher's formatting or copy editing

Terms of use: Creative Commons Attribution-Noncommercial-Share Alike





Published in final edited form as:

Cell. 2018 March 22; 173(1): 90–103.e19. doi:10.1016/j.cell.2018.02.036.

Ribosome Levels Selectively Regulate Translation and Lineage Commitment in Human Hematopoiesis

Rajiv K. Khajuria^{1,2,3}, Mathias Munschauer^{2,11}, Jacob C. Ulirsch^{1,2,11}, Claudia Fiorini^{1,2,11}, Leif S. Ludwig^{1,2,11}, Sean K. McFarland^{1,2}, Nour J. Abdulhay^{1,2}, Harrison Specht², Hasmik Keshishian², D.R. Mani², Marko Jovanovic², Steven R. Ellis⁴, Charles P. Fulco², Jesse M. Engreitz², Sabina Schütz⁵, John Lian⁶, Karen W. Gripp⁷, Olga K. Weinberg⁸, Geraldine S. Pinkus⁹, Lee Gehrke⁶, Aviv Regev², Eric S. Lander², Hanna T. Gazda^{2,10}, Winston Y. Lee⁹, Vikram G. Panse⁵, Steven A. Carr², and Vijay G. Sankaran^{1,2,*}

¹Division of Hematology/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA

²Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA ³Berlin-Brandenburg School for Regenerative Therapies, Charité-Universitätsmedizin Berlin, Berlin 13353, Germany ⁴Department of Biochemistry and Molecular Biology, University of Louisville, Louisville, KY 40202, USA

⁵Institute of Medical Microbiology, Department of Medicine, University of Zurich, CH-8006 Zurich, Switzerland ⁶Institute for Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115, USA; Harvard-MIT Program in Health Sciences and Technology, Cambridge, MA 02139, USA ⁷Division of Medical Genetics, A. I. duPont Hospital for Children, Wilmington, DE 19803, USA ⁸Department of Pathology, Boston Children's Hospital, Boston, MA 02115, USA ⁹Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA ¹⁰Division of Genetics and Genomics, Manton Center for Orphan Disease Research, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA

SUMMARY

*Corresponding Author and Lead Contact: V.G.S. (sankaran@broadinstitute.org).

¹¹These authors contributed equally to this work.

DECLARATION OF INTERESTS

There are no competing interests to disclose.

AUTHOR CONTRIBUTIONS


Conceptualization, R.K.K., J.C.U., and V.G.S.; Methodology, R.K.K., M.M., J.C.U., C.F., L.S.L., S.K.M., and V.G.S.; Formal Analysis, R.K.K., M.M., J.C.U., C.F., L.S.L., S.K.M., D.R.M., and V.G.S.; Investigation, R.K.K., M.M., J.C.U., C.F., L.S.L., S.K.M., N.J.A., H.S., H.K., D.R.M., M.J., S.R.E., C.P.F., J.M.E., S.S., J.L., K.W.G., O.K.W., G.S.P., L.G., A.R., E.S.L., H.T.G., W.Y.L., V.G.P., S.A.C., and V.G.S.; Resources, J.C.U., S.K.M., J.M.E., and V.G.S.; Writing – Original Draft, R.K.K., M.M., J.C.U., and V.G.S.; Writing – Review & Editing, R.K.K. and V.G.S. with input from all authors; Visualization, R.K.K., M.M., J.C.U., C.F., L.S.L., S.K.M., and V.G.S.; Supervision, A.R., E.S.L., S.A.C., and V.G.S.; Funding Acquisition, V.G.S.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Blood cell formation is classically thought to occur through a hierarchical differentiation process, although recent studies have shown that lineage commitment may occur earlier in hematopoietic stem and progenitor cells (HSPCs). The relevance to human blood diseases and the underlying regulation of these refined models remain poorly understood. By studying a genetic blood disorder, Diamond-Blackfan anemia (DBA), where the majority of mutations affect ribosomal proteins and the erythroid lineage is selectively perturbed, we are able to gain mechanistic insight into how lineage commitment is programmed normally and disrupted in disease. We show that in DBA, the pool of available ribosomes is limited, while ribosome composition remains constant. Surprisingly, this global reduction in ribosome levels more profoundly alters translation of a select subset of transcripts. We show how the reduced translation of select transcripts in HSPCs can impair erythroid lineage commitment, illuminating a regulatory role for ribosome levels in cellular differentiation.

ETOC

A global reduction in ribosome levels in Diamond-Blackfan anemia profoundly alters translation of a select subset of transcripts thereby impeding erythroid lineage commitment.



INTRODUCTION

Blood cell production or hematopoiesis serves as a paradigm for cellular differentiation more generally in physiologic systems (Orkin and Zon, 2008). Extensive work has revealed a hierarchical progression of differentiation, where increasingly more lineage-restricted progenitors are produced, ultimately giving rise to lineage committed progenitors and precursors that eventually form mature circulating blood cells (Doulatov et al., 2012; Orkin and Zon, 2008). These observations have served as a framework for understanding the molecular regulation of hematopoiesis and how this process can be perturbed in disease. However, the majority of studies characterizing hematopoiesis in humans and mice have required analysis of bulk cell populations. Recent work, enabled through single cell analyses and refined phenotypic markers, has shown that hematopoietic differentiation may progress

in a distinct manner, where lineage commitment occurs in early hematopoietic stem and progenitor cells (HSPCs) that then undergo orderly differentiation to produce mature circulating blood cells (Notta et al., 2016; Paul et al., 2015; Perie et al., 2015; Velten et al., 2017).

While considerable insight into lineage commitment from HSPCs has been gained at the transcriptional level (Notta et al., 2016; Paul et al., 2015), the repertoire of molecular regulators of this process remains to be fully defined and functionally characterized. Groundbreaking studies have revealed the key role of post-transcriptional regulation in the maintenance of hematopoietic stem cells (Signer et al., 2014; van Galen et al., 2014). The importance of such regulation is emphasized by the observation that only a fraction of the variation in cellular protein levels can be explained through transcriptional changes (Jovanovic et al., 2015; Schwanhausser et al., 2011). Importantly, studies of protein synthesis rates during hematopoiesis have indicated that dramatic changes occur during the early stages of lineage commitment (Signer et al., 2014). However, the functional consequences of such changes in protein synthesis rates for lineage commitment remain largely unexplored.

Diamond-Blackfan anemia (DBA) is a unique blood disorder where erythroid precursors and progenitors are selectively reduced in the bone marrow of patients, while all other lineages are ostensibly produced normally (Iskander et al., 2015; Nathan et al., 1978). Extensive studies have shown that the defect present in DBA appears to occur in early progenitors that are quantitatively reduced, but the few cells that do persist undergo normal terminal maturation (Nathan et al., 1978; Ohene-Abuakwa et al., 2005). The majority of DBA cases are caused by heterozygous loss-of-function mutations in one of 18 different ribosomal protein (RP) genes, resulting in RP haploinsufficiency (Mirabello et al., 2017). Despite extensive studies, the mechanisms by which a defect in RPs could cause a selective absence of erythroid cells within the hematopoietic compartment, while allowing for normal differentiation of other lineages, has remained a mystery (Sankaran and Weiss, 2015). Through studies of rare individuals with a diagnosis of DBA, we identified mutations in the key lineage-determining hematopoietic transcription factor *GATA1* that can cause DBA (Sankaran et al., 2012). Motivated by these observations, we were able to show that RP haploinsufficiency results in reduced translation of *GATA1* mRNA and the erythroid defects present in DBA patient cells could largely be rescued by increasing *GATA1* protein levels (Ludwig et al., 2014). However, despite this insight into the role of *GATA1* in DBA pathogenesis, the mechanisms underlying such translational changes and the stages of hematopoiesis at which these alterations occur remain undefined.

DBA is a unique experiment of nature that presents an opportunity to better define the molecular mechanisms by which defects in the ribosome can selectively impact commitment to the erythroid, but not other hematopoietic lineages. Hence, mechanistic studies of DBA not only allow us to gain insight into the pathogenesis of this disease, but also provide us with an opportunity to better understand how protein translation may play a role in hematopoietic lineage commitment more generally. Here we use human genetics to better define the role of ribosomal alterations *in vivo*, biochemical and proteomic studies to interrogate ribosome levels and composition in human hematopoietic cells, ribosome

hypothesized that ribosome levels may have a selective role in human hematopoietic lineage commitment.

Molecular Lesions Underlying DBA Reduce Ribosome Levels in Hematopoietic Cells

Given the observations in yeast that the TSR2 ortholog is necessary for effective ribosome biogenesis and lesions in this gene reduce overall ribosome levels (Schutz et al., 2014), we wanted to interrogate the alterations in ribosome levels in HSPCs undergoing commitment to the erythroid lineage and in hematopoietic cell lines. Similar to the characterized role of RPs in the biogenesis of mature ribosomes (Henras et al., 2015; Robledo et al., 2008), we found that suppression of TSR2 in human hematopoietic cells resulted in reduced levels of the 18S rRNA, with accumulation of its precursor, 18SE (Figures 2A and S2A–B). Such a defect would impair production of the mature ribosome and thus limit the overall levels of ribosomes in the cytoplasm available for translation. Importantly, these defects are consistent with the lesions in ribosome maturation characterized in yeast with deletion of the TSR2 ortholog (Schutz et al., 2014). However, as the stages of ribosome biogenesis do vary between species (Preti et al., 2013), some difference in the precise nature of the impairment during this process is notable (Schutz et al., 2014).

We next investigated if there were alterations in the levels of actively translating ribosomes by creating DBA-associated molecular lesions, including suppression of TSR2, RPS19 (eS19), RPL5 (uL18), RPS24 (eS24), and RPL11 (uL5). We consistently observed reduced content of ribosomes in the cells using quantitative polysome profiling from similar numbers of cells and through quantification of a variety of RP levels in whole cell lysates from both primary hematopoietic cells and cell lines (Figures 2B–D and S2C–Q). We found an overall reduction of 1.3 – 4.1-fold in the level of monosomes and 1.6 – 2.2-fold in the level of polysomes in primary hematopoietic cells (Figures 2E–F). This correlated well with the quantification of overall RP levels in these cells (Figures 2C and S2M–Q). Importantly, lesions in a single RP would generally suppress the protein levels of other RPs, particularly among those found in the same subunit as the primary molecular lesion (Figures 2B–C and S2H–Q). These data collectively point toward an outcome of reduced ribosome levels with a diverse group of DBA-associated molecular lesions in differentiating HSPCs. To bolster these findings, given that rRNAs play a key role in the formation of the ribosome, we used a selective inhibitor of RNA polymerase I rRNA transcription (CX-5461) (Bywater et al., 2012) to show that rRNA inhibition more profoundly perturbed erythroid lineage commitment, as compared to other myeloid lineages and severely impaired GATA1 protein production (along with RPs) concomitantly (Figures 2G–H).

Verification of Constant Ribosome Composition in Human Hematopoietic Cells with DBA-Associated Molecular Lesions

Our results have suggested that molecular lesions resulting in DBA can reduce the level of actively translating ribosomes in human hematopoietic cells. These results in tandem with the *in vivo* findings from TSR2 mutant patients suggest, but do not formally prove, that reduced ribosome levels may be sufficient to result in impaired erythroid lineage commitment in HSPCs. Recent studies have suggested that RP mutations may result in altered ribosome composition in some contexts (Shi et al., 2017). We therefore wanted to

directly interrogate the protein composition of actively translating ribosomes in the setting of DBA-associated lesions to understand whether such changes may occur in human hematopoietic cells. We performed quantitative high-coverage tandem-mass-tag (TMT) mass spectrometry in human hematopoietic cells to measure the expression of all RPs. We fractionated cells by sucrose gradient sedimentation and collected monosomes (a single ribosome), light polysomes (2–4 ribosomes), and heavy polysomes (> 5 ribosomes) from control cells or those with DBA-associated perturbations, including haploinsufficiency of RPS19 and RPL5 or suppression of TSR2 (Figure 3A). Peptides for RPs were highly enriched in the mass spectrometry data: 77 out of 80 RPs were detectable by two or more unique peptides, and estimates of protein abundance were robust across biological replicates (Figures S3A–F). Strikingly, although we observed altered polysome profiles and cellular RP abundance, the average composition of RPs within monosomes, light polysomes, and heavy polysomes was largely invariant between controls and DBA-associated molecular lesions (Figures 3B–D and S3G–I). The protein expression of the targeted or associated RPs did not deviate significantly from that of the other RPs (based on Studentized residuals, Figures S3G–I), strongly supporting the concept that DBA results from decreased ribosome abundance, rather than from formation of ribosomes that have a distinct protein composition. The composition of ribosome-associated proteins was also analyzed and we found no consistent alteration of these proteins in the presence of DBA-associated molecular lesions (Figures S3J–K). We note that because our assay measures total protein levels within a given cellular fraction, we cannot completely exclude the possibility that the pool of actively translating ribosomes is comprised of ribosomes with variable composition or that DBA-associated lesions could result in conformational changes in the ribosome that then alter translation. However, these possibilities seem unlikely, given the structural stability of the ribosome (Khatter et al., 2015) and the normal, albeit reduced, ribosomal maturation we observe. Therefore, our results from human genetic and biochemical studies of DBA-associated lesions lead to a model whereby the perturbation of hematopoietic differentiation observed arises from a reduced number of ribosomes per cell.

Defining Transcripts Whose Translation is Most Sensitive to DBA-Associated Molecular Lesions

Having concluded that ribosome levels play a critical role in the lineage commitment defect observed in DBA from complementary human genetic and biochemical/proteomic studies, we aimed to better understand the consequences of decreased ribosome levels on translation. To gain global insight into changes in translation that occur with such perturbations in primary human HSPCs undergoing erythroid lineage commitment, we performed ribosome profiling (Ingolia, 2016; Mills et al., 2016). This technique involves measuring translational efficiency (TE), by comparing the levels of ribosome-associated mRNA footprints to the total mRNA for each gene. For biological replicates of RPL5 and RPS19 suppression, we obtained both ribosome-protected footprints (RPFs) and matching mRNA-sequencing (mRNA-seq); the RPFs were of high quality, as assessed by expected RPF size, CDS enrichment, and triplet periodicity (Figures 4A–B and S4A–B; Table S3). Changes in transcription and translation appeared to be largely similar between RPS19 and RPL5 haploinsufficiency (Figure 4C), consistent with the concept that DBA-associated lesions cause a common set of molecular changes in human HSPCs undergoing erythroid

differentiation. Importantly, changes in transcription and translation were largely independent (Figures 4D and S4C), emphasizing the value of ribosome profiling (Ingolia, 2016).

Notably, the RP genes globally showed the greatest decrease in TE with RP haploinsufficiency (the top 10 of 557 KEGG, REACTOME, and BIOCARTA pathways are primarily composed of RP genes), despite relatively unchanged mRNA levels (Figure 4E). This observation suggests that RPs are co-regulated at the translational level, which would allow cells to maintain RP stoichiometry. While translational co-regulation of RPs has been demonstrated downstream of mTOR signaling (Hsieh et al., 2012; Thoreen et al., 2012), our findings show, similar to observations made in yeast (Thompson et al., 2016), that co-regulation of RP translation can also occur in the setting of RP haploinsufficiency in human hematopoietic cells. The extent to which the ubiquitin-dependent degradation of RPs (Sung et al., 2016) plays an additional role in maintaining homeostasis is unclear. However, our data suggest that the reduction of ribosome levels observed in the setting of RP haploinsufficiency (Figures 2 and S2) is largely promoted through reduced translation of RP mRNAs.

At a false discovery rate (FDR) of 10%, we identified a selective set of 525 transcripts whose TE was particularly sensitive to and down-regulated by RP haploinsufficiency (Figure 4D; Table S4). We confirmed our previous finding that translation of *GATA1* mRNA is significantly decreased by ~2-fold in differentiating HSPCs with RP haploinsufficiency (Ludwig et al., 2014) (Figure 4F; Table S4). A subset of the down-regulated transcripts are essential for growth in hematopoietic cells (Wang et al., 2015) and are substantially up-regulated during early erythropoiesis (between CD34⁺ and proerythroblast (ProE) stages of normal human erythropoiesis (Li et al., 2014)), consistent with the stages of perturbation observed in DBA patients (Figure S4D; Table S4). This observation suggests that the reduced translation of multiple transcripts that are up-regulated at the early stages of erythroid lineage-specification from HSPCs, including *GATA1*, plays a key role in the *in vivo* phenotypes observed in DBA. Importantly, in this context, we note that mutations in *GATA1* are sufficient to cause DBA in rare patients (Sankaran et al., 2012) and some genes that are downregulated at the translational level, such as the ribosome-associated protein RNH1, have been shown to have additional key roles in the regulation of *GATA1* mRNA translation (Allam et al., 2014). In concert with previous genetic and rescue experiments performed in DBA patient samples (Ludwig et al., 2014), our results suggest that a number of ribosome-associated factors are translationally down-regulated in the setting of RP haploinsufficiency and many of these lesions potentially result in the coordinated impairment of *GATA1* mRNA translation as a common downstream pathogenic mechanism.

We next sought to determine if these RP haploinsufficiency-sensitive transcripts shared similar features to gain insight into the mechanisms of lineage commitment during human hematopoiesis and how this process can be perturbed in diseases like DBA. Interestingly, we found that the RP haploinsufficiency-sensitive transcripts were on average shorter in overall length, more efficiently translated under baseline conditions, and encoded more abundantly expressed proteins in unperturbed primary human erythroid progenitors (Gautier et al., 2016) (Figures 4G and S4D). Of note, short mRNA length has been shown to be associated

with efficient translation in other contexts (Thompson et al., 2016), although this feature alone may not be sufficient to mediate translational control.

Much of the underlying regulation of protein translation is mediated by the 5' untranslated region (5' UTR) of transcripts (Hinnebusch et al., 2016; Shah et al., 2013). To fully interrogate this variation, we comprehensively defined 5' UTRs present in hematopoietic cells using cap analysis gene expression (CAGE) sequencing, which can often vary from annotated 5' UTRs (Figure S5A). Using such data, we found that the 5' UTRs of down-regulated transcripts were 42 nucleotides shorter on average, were predicted to have less complex secondary structure, and contained fewer in-frame and out-of-frame upstream start codons (uAUGs) – features associated with efficient ribosome initiation and translation in unperturbed cells, including in our data from control HSPCs undergoing erythroid lineage commitment (Hinnebusch et al., 2016; Shah et al., 2013) (Figures 5A and S5B–C). As the 5' terminal oligopyrimidine (5' TOP) motif was originally identified in RP mRNAs (Roepcke et al., 2006), we investigated whether this motif or a similar motif was enriched in those transcripts with reduced TE. We found a significant enrichment for such motifs that was predominantly explained by the down-regulated group of RP mRNAs (Figure S5D), suggesting that translational alterations in RP haploinsufficiency are partially overlapping with, but are distinct from, alterations due to mTOR inhibition where TOP or TOP-like motifs are present in a large subset of mTOR-sensitive transcripts (Hsieh et al., 2012; Thoreen et al., 2012). Further analysis revealed that a number of motifs were nominally enriched across the entire 5' UTR, as well as at the 5' and 3' ends, but no single motif could explain the observed differences in TE between RP haploinsufficiency-sensitive and insensitive transcripts (Figures S5E–F). Altogether, a model of the features investigated here explained 39% of the variation of TE changes in a held-out set of genes, validating the key role that these features have in translational regulation (Hinnebusch et al., 2016; Shah et al., 2013).

Interrogation of 5' UTRs from Hematopoietic Master Regulators Suggests Mechanisms of Lineage Selectivity in DBA

While our ribosome profiling analysis elucidated transcripts within differentiating HSPCs that selectively show increased sensitivity to impaired translation in the setting of DBA-associated molecular lesions, these findings are insufficient to explain the erythroid specificity of DBA. We had noted that most of the transcripts sensitive to RP haploinsufficiency tended to have short and unstructured 5' UTRs – features that are associated with increased translation efficiency under baseline conditions (Figures 5A and S5B). This included the 5' UTR of *GATA1* mRNA. Master regulator transcription factors, such as GATA1, are critical for determining cell identity and promoting lineage specification in physiologic differentiation processes such as hematopoiesis (Doulatov et al., 2012; Orkin and Zon, 2008). Indeed, such master regulator transcription factors are sufficient to allow for dramatic changes in cell state (Srivastava and DeWitt, 2016). We reasoned that perhaps the observed lineage selectivity may occur because no other master regulators of hematopoietic lineage commitment were perturbed by reduced ribosome levels (Paul et al., 2015; Velten et al., 2017). Our results from ribosome profiling suggest that this could be due to 5' UTR-mediated mechanisms. To investigate whether the observed patterns of sensitivity to reduced

ribosome levels may underlie the hematopoietic lineage selectivity, we examined CAGE data generated from unperturbed primary human HSPCs that are comprised of progenitors capable of commitment to multiple lineages. Among a group of 36 well-characterized hematopoietic master regulators known to have key and well-defined roles in lineage commitment (where 29 of these transcription factors were well expressed and had clearly defined TSSs in CAGE data generated from unperturbed primary human HSPCs) (Figure 5B), we found that the majority had significantly longer and more complex 5' UTRs compared with those transcripts sensitive to reduced ribosome levels, with *GATA1* mRNA being a notable exception (Figures 5C–D). Importantly, the overall group of hematopoietic master regulators has significantly longer 5' UTR lengths (2.5 mean-fold difference, $p < 10^{-4}$) and more complex 5' UTR structures (2.8 mean-fold difference in G , $p < 10^{-3}$) than the group of transcripts showing sensitivity to RP haploinsufficiency (Figure 5E–F). Altogether these data suggest that *GATA1* exhibits unique 5' UTR features among hematopoietic master regulators, which may explain its translational sensitivity to reduced ribosome levels and the consequent lineage specific defect observed in DBA. Importantly, we were able to validate this lack of translational downregulation with RP haploinsufficiency for master regulators that were expressed in the differentiating HSPCs: *KLF1*, *TAL1*, *MYB*, *GATA2*, *LMO2*, *RUNX2*, *ETV6*, *KMT2A*, *NFE2*, *FLI1*, *STAT5A*, *STAT3*, *SPI1*, *NOTCH1*, *BCL11A*, *IKZF1* and *XBPI* all showed no major decrease in TE (FDR \downarrow > 10%, log₂ TE fold decrease of < 0.45).

To directly interrogate whether such 5' UTR features may be sufficient to confer baseline variation in translation, we complemented the *GATA1*-null G1E hematopoietic cell line (Weiss et al., 1997) with *GATA1* cDNA harboring 5' UTRs from different hematopoietic master regulators including *GATA1* itself, *LMO2*, *RUNX1*, and *ETV6* - the latter three being longer and having more complex secondary structures than the endogenous *GATA1* 5' UTR (Table S5). Consistent with the hypothesis that other master regulator 5' UTRs should have lower translation efficiency under baseline conditions (Figure 5G) and therefore would be less susceptible to a reduction in ribosome levels, we found that the *GATA1*-induced erythroid differentiation (that correlates with *GATA1* protein levels) was substantially impaired by 5' UTRs from the other hematopoietic master regulators compared with *GATA1* (Figures 5H–J). These data emphasize the unique features of the *GATA1* 5' UTR, in comparison to other hematopoietic master regulator mRNAs, which thereby confer sensitivity to variation in ribosome levels.

Impaired *GATA1* Protein Production in Primary HSPCs from DBA Patients

We have shown that impaired translation of select transcripts, including *GATA1*, occurs with RP haploinsufficiency and consequently reduced ribosome levels, and is accompanied by the functional hematopoietic defects characteristic of DBA. Our analysis suggests that a key common effector of these defects in DBA is *GATA1*. We wanted to confirm the relevance of these findings at the single cell level in hematopoietic progenitors *in vivo* in DBA patients. As primary patient samples are often limited and challenging to obtain, we developed a semi-quantitative immunohistochemistry staining method for *GATA1* protein expression (Lee et al., 2017). We could individually identify and measure the staining intensity of *GATA1* in the nuclei of erythroid precursors and progenitors from bone marrow biopsies

obtained from healthy controls or from DBA patients (Carpenter et al., 2006). We found that DBA patients had a significantly reduced GATA1 staining intensity in such cells (Figures 6 and S6). While some cells did have overlapping intensities, we noted that less mature cells with larger nuclei frequently had reduced staining intensities, suggesting that the defects in DBA arise at the early stages of erythroid lineage commitment. However, immunohistochemistry is limited in our ability to compare stage-matched cells and this analysis could be confounded by variation in erythroid cell composition between DBA patients and controls.

We therefore wanted to identify the stages at which such impairments may arise during *in vivo* human hematopoiesis. Recent work has shown that lineage commitment to the erythroid and other lineages occurs predominantly at the early HSPC stages, rather than occurring at later stages of differentiation as classically inferred through analysis of heterogeneous bulk cell populations (Notta et al., 2016; Paul et al., 2015; Perie et al., 2015; Velten et al., 2017). Indeed, *GATA1* mRNA shows initial expression in human HSPCs within the most primitive CD34⁺CD38⁻ compartment (Notta et al., 2016). We had previously demonstrated that human HSPCs show no difference in *GATA1* mRNA expression when comparing healthy donors to patients with DBA (Ludwig et al., 2014). To interrogate GATA1 protein expression at the single cell level, we developed an intracellular flow cytometric detection approach. We utilized an *in vitro* erythroid differentiation protocol from human HSPCs to interrogate GATA1 expression during this differentiation process (Giani et al., 2016; Kim et al., 2017). We found that GATA1 was expressed at low levels in a subset of the HSPCs prior to initiation of differentiation. As expansion and differentiation proceeded, there was an initial up-regulation of GATA1 in many cells and a progressive increase in expression among the primitive CD34⁺CD38⁻ and more differentiated CD34⁺CD38⁺ HSPC populations (Figure 7A). With differentiation, robust and high-level GATA1 protein expression was seen in lineage committed CD235a⁺CD71⁺ erythroid cells (Figures 7A and S7A). Our findings from this differentiation protocol demonstrate that GATA1 is initially expressed in a subset of HSPCs at low levels and this expression then progressively increases with higher-level expression occurring in erythroid-committed progenitors and precursors.

The observed early expression of GATA1 protein in HSPCs is consistent with the recently described models of hematopoiesis where lineage commitment occurs in such primitive populations and builds upon these findings to delineate a key role for this master transcription factor in this process (Notta et al., 2016; Paul et al., 2015; Perie et al., 2015; Velten et al., 2017). Given the observed expression, we interrogated GATA1 protein expression in single cells from HSPC populations of unperturbed DBA patient or healthy control bone marrow aspirate samples (Figures 7B–C). Interestingly, among patients with *RPL35A*, *RPL5*, or *RPS19* mutations, there was a consistent reduction in GATA1 expression in both CD34⁺CD38⁻ and CD34⁺CD38⁺ HSPC populations (Figure 7C). Despite overall upregulation of GATA1 protein levels during the CD38⁻ to CD38⁺ transition of hematopoietic progenitors, the overall GATA1 levels in individual progenitors remained lower in DBA patients. These observations demonstrate that in uncultured bone marrow specimens from DBA patients with diverse RP mutations, there is a reduction in GATA1 expression at the early HSPC stages. This finding fits with the lineage commitment

impairment characteristic of DBA (Iskander et al., 2015; Nathan et al., 1978) and also supports our mechanistic studies of altered translation in differentiating HSPCs.

DISCUSSION

Recent studies have refined our understanding of hematopoiesis and shown that hematopoietic lineage commitment occurs at the early HSPC stages (Notta et al., 2016; Paul et al., 2015; Perie et al., 2015; Velten et al., 2017). However, the key molecular regulators of lineage commitment and the relevance of these updated models to human disease have not been explored. Here, we have studied a rare genetic blood disorder - DBA - that is characterized by a paucity of erythroid precursors and progenitors, to provide insight into both of these issues. We show that the lesions in DBA arise at the level of HSPCs, consistent with the specification of lineage commitment and differentiation within this primitive cell compartment. We also demonstrate how ribosome levels can play a key role in allowing lineage commitment to productively ensue. Our findings demonstrate how by exploring a rare genetic disorder, we can not only gain insight into the pathogenesis of the specific disease of interest, but also more broadly provide insight into the molecular underpinnings of hematopoietic lineage commitment.

We demonstrate through complementary human genetic and biochemical studies that ribosome levels serve a key role in allowing effective hematopoietic differentiation. A select subset of transcripts is affected by functionally relevant alterations in ribosome levels. Specifically, we found that reduced ribosome levels impaired the translation of transcripts that are normally highly translated and have short/unstructured 5' UTRs over other transcripts. These findings demonstrate the value that ribosome profiling can have to interrogate translation on a global genomic scale and have allowed us to identify the specific liabilities that occur in the setting of reduced ribosome levels (Ingolia, 2016). Our findings complement recent studies showing how protein synthesis undergoes dramatic variation during hematopoiesis (Signer et al., 2014). While the functional role of such tightly regulated protein synthesis rates in hematopoietic stem cells has been examined, the necessity of upregulation in protein synthesis rates for hematopoietic differentiation has not been explored. While in some contexts RP composition may vary (Shi et al., 2017), we find that in the setting of RP haploinsufficiency in hematopoietic cells, no apparent altered composition can be identified. Rather, the impaired lineage commitment characteristic of DBA arises from a reduced cellular level of ribosomes. It is notable that studies in hematopoietic cells have demonstrated that the highest rates of protein synthesis occur in progenitors undergoing erythroid lineage commitment (Signer et al., 2014), which fits with our findings of how ribosome levels can selectively impair erythroid lineage commitment and GATA1 requires one of the highest translation rates among various master regulators of hematopoiesis. Future studies examining the sensitivity to and liabilities arising from reduced ribosome levels in various hematopoietic lineages will provide further insight into this process.

Beyond hematopoiesis, the regulation of ribosome levels is likely to have a key role more broadly in cellular differentiation and tissue homeostasis (Buszczak et al., 2014). Indeed, the broad array of ribosomal disorders, which display highly-specific phenotypes, indicates the

key roles that ribosome levels may have in other contexts and cell types (McCann and Baserga, 2013). Even mutations in RPs themselves can present with a broad range of highly specific phenotypes beyond the paucity of erythroid cells characteristic of DBA. These phenotypes include isolated congenital asplenia (Bolze et al., 2013) and neurodevelopmental disorders (Brooks et al., 2014) in addition to the non-hematopoietic phenotypes notable in DBA patients, such as cleft lip/palate, thumb abnormalities, and other congenital defects (Gazda et al., 2008). It is likely that mechanisms involving impaired translation of specific transcripts, similar to those we identify within the hematopoietic compartment, may have a role in mediating these other phenotypes.

While studies of cellular differentiation have largely focused on transcriptional changes underlying these processes, it is clear that post-transcriptional regulation serves key and largely unappreciated roles in this process. While exploration of such mechanisms is more limited, as compared to the relative ease of interrogating the transcriptome (Tanay and Regev, 2017), advances in approaches such as ribosome profiling suggest that important insight can more broadly be gained into this process through in depth mechanistic studies (Ingolia, 2016). With continued advances in the ability to carry out such approaches in more limited populations of cells, as we have done here with primary human hematopoietic cells, and the increased availability of orthogonal genomic data, more sophisticated insight can be gained into the regulation of this process. In addition, the key advances occurring in the field of human genetics will enable us to better understand how such process can be perturbed in human disease (Casanova et al., 2014), as we have been able to study here for DBA.

STAR★METHODS

CONTACT FOR REAGENT AND RESOURCE SHARING

Requests for further information or reagents may be directed to the Lead Contact, Vijay G. Sankaran (sankaran@broadinstitute.org).

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Primary Cell Culture—CD34⁺ cells were obtained from magnetically sorted mononuclear samples of G-CSF–mobilized peripheral blood from donors and were frozen after isolation. Cells were obtained from the Fred Hutchinson Cancer Research Center, Seattle, USA or the Department of Hematology/Oncology Flow Cytometry Research Facility at Boston Children’s Hospital. Cells were thawed and washed into PBS with 1% human AB serum (Atlanta Biologicals), pelleted and then seeded in differentiation medium containing IMDM with 2% human AB plasma, 3% human AB serum, 1% P/S, 200 µg/mL holo-transferrin, 10 ng/mL SCF (PeproTech, Inc.), 1 ng/mL IL-3 (PeproTech, Inc.) and 3 U/mL erythropoietin (EPO) (Amgen). Where an expansion phase is indicated, CD34⁺ cells were cultured in StemSpan SFEM II medium (STEMCELL Technologies) supplemented by 1X CC100 (containing FLT3 ligand, stem cell factor (SCF), IL-3, and IL-6, STEMCELL Technologies) for 5 days prior to differentiation. Cells were maintained at a density between 0.1×10^6 and 0.5×10^6 cells per milliliter, with medium changes every other day as necessary. Cells were incubated at 37 °C with 5% CO₂.

293T and K562 Cell Culture—293T cells (ATCC) were maintained in DMEM with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (P/S). K562 human erythroid cells (ATCC) were maintained at a density between 0.1×10^6 and 1×10^6 cells per milliliter in RPMI 1640 medium supplemented with 10% FBS and 1% P/S. Cells were incubated at 37 °C with 5% CO₂.

G1E Cell Culture—G1E cells (Weiss et al., 1997) were cultured in IMDM with 15% FCS, 1% P/S., 4.5×10^{-5} M Monothioglycerol (MTG), 50ng/ml SCF and 2 U/ml EPO at a density between 0.1×10^6 and 1×10^6 cells per ml, with medium changes every day as necessary. Cells were incubated at 37 °C with 5% CO₂.

METHOD DETAILS

Lentiviral Vectors and Infection—The shRNA constructs targeting human *TSR2* (shTSR2-1 and shTSR2-2, RefSeqID NM_058163), human *RPS19* (shRPS19-1 and shRPS19-2, RefSeqID NM_001022), human *RPS24* (shRPS24-1 and RPS24-2, RefSeq ID NM_001026), human *RPL5* (shRPL5-1 and RPL5-2 RefSeq ID NM_000969) and human *RPL11* (shRPL11-1 and RPL11-2 RefSeq ID NM_000975) were obtained from the Mission shRNA collection (Sigma-Aldrich). The sequences of the shRNAs used in this study are listed in the Key Resources Table.

The lentiviral vectors pLKO-GFP and pLKO.1 targeting Luciferase (shLuc) (Genetic Perturbation Platform of the Broad Institute of MIT and Harvard) were used as controls. Rescue experiments were performed as described previously (Ludwig et al., 2014) by co-transduction of human erythroid cells with shRNAs targeting TSR2 and either the HMD control or HMD-GATA1, which contain the respective cDNAs. Double-transduced cells were identified by puromycin selection and GFP expression driven by an IRES-GFP in the HMD vector.

For lentivirus production, 293T cells were transfected with pVSV-G and pDelta8.9 using FuGene 6 reagent (Promega) according to the manufacturer's protocol. The medium was changed the day after transfection to the appropriate culture medium, respectively. After 30 h, viral supernatant was collected and filtered using a 0.45 µm filter immediately before infection of primary hematopoietic or K562 cells in a 6-well plate at a density of 200,000–500,000 cells per well in the presence of 8 g/ml polybrene (Millipore). The cells were spun at 2,000 r.p.m. for 90 min at 22 °C and left in viral supernatant overnight. The medium was replaced the morning after infection. Puromycin selection of infected cells was started 36 h after infection with 1 µg/ml for primary hematopoietic cells or 2 µg/ml for K562 cells. Infection efficiency was between 50–80% for primary hematopoietic cells and >95% for K562 cells as assessed by flow cytometry of pLKO-GFP infected cells.

Yeast Strains and Plasmids—Preparation of media, yeast transformations and genetic manipulations were performed according to established procedures (Schutz et al., 2014). Plasmids used in this study are listed in Table S6. Details of plasmid construction will be provided upon request. All recombinant DNA techniques were performed according to established procedures using E. coli XL1 blue cells for cloning and plasmid propagation. Point mutations in human *TSR2* were generated using the QuikChange site-directed

mutagenesis kit (Agilent Technologies). All cloned DNA fragments and mutagenized plasmids were verified by sequencing. The PGAL1-TSR2 strain transformed with indicated plasmids in Figure 1 was spotted in 10-fold dilutions on selective glucose containing plates and grown at indicated temperatures for 3–7 days.

Quantitative RT-PCR—Isolation of RNA was performed using the RNeasy Plus Mini Kit (Qiagen). An on-column DNase (Qiagen) digestion was performed according to the manufacturer's instructions. RNA was quantified by a NanoDrop spectrophotometer (Thermo Scientific). Reverse transcription was carried out using the iScript cDNA synthesis kit (Bio-Rad). Real-time PCR was performed using the CFX96 Real-time PCR detection system (Bio-Rad) and iQ™ SYBR® Green Supermix (Bio-Rad). Quantification was performed using the comparative C_T method. Normalization was performed using β-actin mRNA as a standard. The primers used for quantitative RT-PCR are listed in Table S6.

Western Blotting—Cells were harvested 5 days post-infection or at 72 h of treatment with the polymerase I inhibitor CX-5461 (Millipore), washed twice in PBS, resuspended in RIPA lysis buffer (50 mM Tris-HCl at pH 7.4, 150 mM NaCl, 0.1% SDS, 1% NP-40, 0.25% sodium deoxycholate, 1 mM DTT) supplemented with 1× Complete Protease Inhibitor Cocktail (Roche) and incubated for 30 min on ice. After centrifugation at 15,000 r.p.m. for 10 min at 4 °C to remove cellular debris, the supernatant was transferred to a new tube, supplemented with Laemmli sample buffer (Bio-Rad) and incubated for 10 min at 90 °C. Equal amounts of proteins were separated by SDS gel electrophoresis using the Mini-PROTEAN® TGX™ gel system (Bio-Rad) and Tris/glycine/SDS running buffer. Subsequently, proteins were transferred onto a PVDF membrane (Millipore) using Tris/glycine transfer buffer. Membranes were blocked with 3% BSA-PBST for 1 h and probed with GATA1 goat polyclonal antibody (M-20, sc-1234, Santa Cruz Biotechnology) at a 1:500 dilution, TSR2 rabbit polyclonal antibody (ab155810, Abcam) at a 1:1,000 dilution, RPS19 mouse monoclonal antibody (WW-4, sc-100836, Santa Cruz Biotechnology) at a 1:500 dilution, RPL5 goat polyclonal (D-20, sc-103865, Santa Cruz Biotechnology) at a 1:500 dilution, RPL11 goat polyclonal (N-17, sc-25931, Santa Cruz Biotechnology) at a 1:500 dilution, RPS20 goat polyclonal (G-15, sc-55035, Santa Cruz Biotechnology) at a 1:500 dilution, RPS24 rabbit polyclonal (ab102986, Abcam) at a 1:1,000 dilution, RPS26 rabbit polyclonal (ab104050, Abcam) at a 1:1,000 dilution, RPSA rabbit polyclonal (ab137388, Abcam) at a 1:1,000 dilution, RPL28 rabbit polyclonal (FL-137, sc-50362, Santa Cruz Biotechnology) at a 1:1,000 dilution, EPOR rabbit polyclonal (M-20, sc-697, Santa Cruz Biotechnology) at a 1:500 dilution, STAT5A rabbit polyclonal (C-17, sc-835, Santa Cruz Biotechnology) at a 1:500 dilution, JAK2 rabbit polyclonal (HR-758, sc-278, Santa Cruz Biotechnology) at a 1:500 dilution, Bystin mouse monoclonal (A-10, sc-271722, Santa Cruz Biotechnology) at a 1:1,000 dilution, Lamin B goat polyclonal (C-20, sc-6216, Santa Cruz Biotechnology) at a 1:500 dilution, ACTB mouse monoclonal (AC-15, A1978, Sigma Aldrich) at a 1:10,000 dilution or GAPDH mouse monoclonal antibody (6C5, sc-32233, Santa Cruz Biotechnology) at a 1:1,000 dilution in 3% BSA-PBST over-night at 4 °C. Membranes were washed four times with PBST, incubated with donkey anti-mouse, anti-goat or anti-rabbit peroxidase-coupled secondary antibodies (715-035-150, 705-035-147 or 711-035-152, respectively; Jackson ImmunoResearch) at a 1:10,000 to 1:20,000 dilution in

3% BSA-PBST for 1 h at room temperature, washed three times with PBST and incubated for 5 minutes with Clarity western ECL substrate (Bio-Rad). Proteins were visualized by using the ChemiDoc Touch Imaging System (Bio-Rad) or by exposure to scientific imaging film (GE Healthcare Life Sciences). Band intensities were determined with Image Lab (Bio-Rad). Where indicated, separation of nuclear and cytoplasmic fractions was performed with the PARIS™ Kit (Ambion).

Flow Cytometry Analysis and Apoptosis Detection—For flow cytometry analysis, *in vitro* cultured hematopoietic cells were washed in PBS and stained with propidium iodide (PI), 1:20 APC-conjugated CD235a (glycophorin A, clone HIR2, eBioscience), 1:20 Pacific Blue-conjugated CD41a (HIP8, BioLegend), 1:20 Pacific Blue-conjugated CD11b (ICRF44, BioLegend) or 1:25 APC-conjugated TER-119 (TER-119, eBioscience). For apoptosis analysis, the Annexin V-APC staining kit was used according to the manufacturer's instructions (550474, BD Pharmingen). FACS analysis was conducted on a BD Bioscience Canto II flow cytometer. Data were analyzed using FlowJo 10.0.7 (TreeStar).

Intracellular GATA1 Staining—Uncultured, frozen cells from healthy individuals' and DBA patients' bone marrow specimens were recovered and stained for comparison of GATA1 protein expression in HSPC populations. Primary human adult HSPCs (from mobilized peripheral blood derived from G-CSF treated donors) were collected and stained at different time points of an *in vitro* culture system with expansion and differentiation phases to assess GATA1 expression at different stages of erythroid differentiation from unperturbed HSPCs. For each experiment, K562 and 293T cells were used as internal positive and negative controls, respectively. Cells were rinsed with 0.5% BSA in 1X PBS and stained for surface markers with CD34 Alexa488 (clone 581, BioLegend) and CD38 BV421 (clone HB7, BioLegend), or for CD71 PE (clone OKT9, eBioscience) and CD235a FITC (clone HIR2, BioLegend). Cells were then fixed, permeabilized and stained for GATA1 according to the BD Pharmingen™ Transcription Factor Buffer Set protocol (BD Pharmingen). 1:100 GATA1 rabbit monoclonal antibody EP2819Y (Abcam) or 1:200 rabbit monoclonal IgG isotype control were used as primary antibodies and polyclonal goat anti-rabbit IgG (H+L) Alexa647 conjugate (Jackson) was used as secondary antibody. Cells were run on BD Accuri C6 or BD Fortessa flow cytometers. Data were analyzed using FlowJo 10.2 (TreeStar).

rRNA Processing Examination—Northern blot analysis was done as described previously (Farrar et al., 2014). Bioanalyzer traces were obtained on an Agilent 2100 system with RNA Pico 6000 chips, sample processing was done according to the manufacturer's instructions.

Polysome Profiling—Cells were incubated with 100 µg/ml of cycloheximide (Sigma Aldrich) for 5 min at 37 °C, washed twice with ice-cold PBS containing 100 µg/ml of cycloheximide and lysed in 10 mM Tris-HCl (pH 7.4), 5 mM MgCl₂, 100 mM KCl, 1% Triton X-100, 3 mM DTT, 100 µg/ml cycloheximide, 500 U/ml RNasin (Promega) and 1× Complete Protease Inhibitor, EDTA-free (Roche) as well as 1× Protease Inhibitor Set (without EDTA) (G-Biosciences). Polysomes were separated on a 10–50% (or 10–45%)

linear sucrose gradient containing 20 mM Tris-HCl (pH 7.4), 5 mM MgCl₂, 100 mM KCl, 3 mM DTT, 100 µg/ml cycloheximide and 20 U/ml SUPERase• In™ RNase Inhibitor (Ambion) and centrifuged at 36,000 r.p.m. for 2 h in a SW41 rotor in an L8–80M ultracentrifuge (Beckman Coulter). For mass spectrometry samples, gradients were fractionated using a Biocomp Gradient Station fractionator. Absorbance at 254 nm was used to visualize the gradients using an Econo UV monitor (Bio-Rad). Further processing for mass spectrometry analyses is described below.

Mass Spectrometry—Collected fractions for monosomes (a single ribosome), light polysomes (2–4 ribosomes) and heavy polysomes (> 5 ribosomes) from K562 cells with indicated knockdown were pooled, respectively. Proteins from respective fractions were precipitated with deoxycholate-trichloroacetic acid as described previously (Reschke et al., 2013), protein pellets were resuspended in 50 mM Tris HCl buffer containing 8 M Urea at pH8. Protein concentrations of the samples were estimated by BCA protein assay (ThermoFisher Scientific). Samples were reduced with 20 mM dithiothreitol at 37 °C for 30 min, and alkylated with 50 mM iodoacetamide at room temperature in the dark for 30 min. Urea concentration was diluted to 2 M with 50 mM Tris HCl pH8 prior to Lys-C digestion (Wako) at 1:50 (w:w) enzyme to substrate ratio at 30 °C for 2 h with mixing on the shaker at 850 r.p.m.. Urea was further diluted to less than 1 M prior to overnight digestion with trypsin (Promega) with 1:50 (w:w) enzyme to substrate ratio at 37 °C with shaking at 850 r.p.m.. Digestion was terminated with formic acid to a final concentration of 1%. The digests were desalted on vacuum manifold using Oasis HLB 1cc (30 mg) reversed phase cartridges (Waters) with 0.1% formic acid/water and 0.1% formic acid/80% acetonitrile as buffers A and B, respectively. Briefly, cartridges were conditioned with 3 × 500 µl buffer B followed by equilibration with 4 × 500 µl buffer A. After loading the digests at a reduced flow rate, they were washed with 3 × 750 µl buffer A and eluted with 3 × 500 µl buffer B. Eluates were frozen and dried by vacuum centrifugation. Digests were reconstituted in 100 µl of 0.1% formic acid /3% acetonitrile and post-digestion concentrations were determined by NanoDrop 2000 (ThermoFisher Scientific). Based on the post-digestion concentration, 30 µg aliquots were prepared, dried to dryness by vacuum centrifugation and stored at –80°C. A pooled reference sample was created by mixing equal amounts of the monosome, light and heavy polysome samples from both replicates of the shLuc control cell line and aliquoted at 30 µg, dried to dryness by vacuum centrifugation and stored at –80°C.

TMT ten-plex reagent (ThermoFisher Scientific) was used for isobaric labeling of samples. Sample labeling was designed so that duplicate samples from all four cell lines representing a given sucrose gradient fraction (monosomes, light polysomes, heavy polysomes) were contained within the same TMT ten-plex experiment with the reference sample included as the 9th channel in all three TMT ten-plex experiments. The 10th channel was omitted from the experiment. Table S7 summarizes TMT reagent channel line-up for all the samples.

Thirty microgram dried aliquot of each sample was labeled with TMT ten-plex reagent following manufacturer's instructions (ThermoFisher Scientific). Samples were reconstituted in 30 µl 50 mM HEPES buffer. 800 µg of each TMT reagent was reconstituted in 41 µL acetonitrile and 12.3 µL of the resulting solution was added to each sample, mixed and incubated at room temperature for 1 h with shaking at 850 r.p.m.. Three microliters of each

sample was used to check label incorporation by LC-MS/MS prior to quenching the reaction. Once satisfied with labeling efficiency (> 95% label incorporation) the reactions were quenched by adding 2.4 μL of 5% hydroxylamine to a 0.08 $\mu\text{g}/\mu\text{L}$ concentration and incubated at room temperature for 15 min with shaking. Labeled samples representing each fraction type along with the pooled reference control were mixed together, dried down and desalted using Oasis HLB 1cc (30 mg) reversed phase cartridges as described above. Eluates were frozen, dried to dryness, and stored at $-80\text{ }^{\circ}\text{C}$.

Samples were reconstituted in 0.1% formic acid/3% Acetonitrile at 1 $\mu\text{g}/\mu\text{L}$ concentration and 1 μL of it was analyzed on Q Exactive Plus mass spectrometer (Thermo Fisher Scientific) coupled to an EASY-nLC 1000 UHPLC system (Proxeon, Thermo Fisher Scientific). Chromatography was performed on a 75 μm ID picofrit column (New Objective) packed in house with Reprosil-Pur C18 AQ 1.9 μm beads (Dr. Maisch, GmbH) to a length of 20 cm. Columns were heated to 50 $^{\circ}\text{C}$ using column heater sleeves (Phoenix-ST). Mobile phases consisted of 0.1% formic acid/3% acetonitrile as solvent A, and 0.1% formic acid/90% acetonitrile as solvent B. Peptides were eluted at 200 nL/min with a gradient of 6 to 35% B in 150 min, 35 to 60% B in 8 min, 60 to 90% B in 3 min, hold at 90% B for 10 min, 90% B to 50% B in 1 min, followed by isocratic hold at 50% B for 10 min. A single Orbitrap MS scan from 300 to 1800 m/z at a resolution of 70,000 with AGC set at $3e6$ was followed by up to 12 ms/ms scans at a resolution of 35,000 with AGC set at $5e4$. MS/MS spectra were collected with normalized collision energy of 29 and isolation width of 1.6 amu with isolation offset set to 0.3 amu. Dynamic exclusion was set to 20 s, and peptide match was set to preferred. Data analysis is described below.

RNA Polymerase I Inhibition—Human CD34⁺ cells were cultured in erythroid differentiation medium as described above. Treatment with the RNA polymerase I inhibitor CX-5461 (Millipore) was started on day 3 of differentiation. Flow cytometry analysis was performed at 72 hours of CX-5461 treatment, with propidium iodide (eBioscience), 1:40 APC-conjugated CD235a (glycophorin A, clone HIR2, eBioscience), 1:40 FITC-conjugated CD41a (clone HIP8, eBioscience) and 1:40 FITC-conjugated CD11b (clone ICRF44, BioLegend). Samples were run on a BD LSRFortessa. Protein lysates for Western blot analyses were collected at 72 hours of CX-5461 treatment. The Western blot procedure is described above.

Ribosome Profiling—Lysates were prepared as described under polysome profiling and partitioned for either ribosome footprint profiling or mRNA sequencing. Total RNA was extracted with the Direct-zolTM RNA MiniPrep Plus w/TRI Reagent[®] Kit (Zymo Research) according to the manufacturer's instructions. Total mRNA was poly-A selected using the NEBNext[®] Poly(A) mRNA Magnetic Isolation Module (New England Biolabs) according to the manufacturer's instructions. mRNA seq libraries were generated as described previously (Engreitz et al., 2013). Ribosome footprinting and subsequent library preparation of ribosome protected RNA fragments (RPFs) was performed with the Truseq Ribo Profile (Mammalian) Kit (Illumina) according to the manufacturer's protocol. rRNA removal was performed by using the Ribo-Zero Gold rRNA Removal Kit (Illumina). RNase I (Ambion) digestion was done at a concentration of 2.5 U/ μL lysate. RPFs were purified with MicroSpin

S-400 columns (GE Healthcare Life Sciences). All libraries were sequenced on a HiSeq 2500 system (Illumina).

5'UTR-GATA1 Construct Cloning—5' UTRs were defined from CD34⁺ HSPC CAGE data. For cloning, the RUNX1 and GATA1 5'UTR-GATA1 constructs were synthesized by Integrated DNA Technologies (IDT). Alternatively, the GATA1 coding region was synthesized by IDT, and joined to PCR amplified ETV6 and LMO2–5'UTR fragments by overlap PCR and TOPO cloned (Zero Blunt TOPO PCR Cloning Kit, Invitrogen). Finally, all fragments were cloned into the U6_optisgRNA_modEF1s_p2A_GFP vector using BamHI and XhoI restriction sites. All constructs were verified by Sanger sequencing. Relevant construct sequences are shown in Table S5.

QUANTIFICATION AND STATISTICAL ANALYSIS

Whole Exome Sequencing—The cousins described in this manuscript underwent whole exome sequencing at the Broad Institute (dbGAP accession phs000474.v2.p1). In this study, whole exome sequencing and variant calling was performed as previously reported (Sankaran et al., 2012). Coverage across protein coding regions was calculated using Picard tools (Table S2). Variant Effect Predictor v83 (<https://www.ensembl.org/info/docs/tools/vep/index.html>) and the dbNSFP database v3.1 (<https://sites.google.com/site/jpopgen/dbNSFP>) were used to annotate the variant call file (VCF). We did not identify any rare (defined as 0.01% allele frequency in ExAC v0.3) (Lek et al., 2016) damaging (missense or loss of function) mutations in any of the known DBA genes (*RPS19* (*revised nomenclature* (<http://www.bangroup.ethz.ch/research/nomenclature-of-ribosomal-proteins.html>): *eS19*), *RPL5* (*uL18*), *RPL11* (*uL5*), *RPL35A* (*eL33*), *RPL35* (*uL29*), *RPS26* (*eS26*), *RPS24* (*eS24*), *RPS17* (*eS17*), *RPS7* (*eS7*), *RPS10* (*eS10*), *RPL26* (*uL24*), *RPS29* (*uS14*), *RPS28* (*eS28*), *RPS27* (*eS27*), *RPL27* (*eL27*), *RPL15* (*eL15*), *RPL31* (*eL31*), *RPL18* (*eL18*), *GATA1*) or in any other ribosome protein coding genes that fit the predicted dominant or X-linked inheritance pattern. We thus investigated all genes for rare and predicted damaging mutations that fit either of these inheritance patterns (Table S1). Subsequently, we identified chrX:54469851:A>G in *TSR2* as the most likely candidate and verified this mutation by Sanger sequencing.

ExAC Gene Constraint Analyses—The ExAC v0.3 database, containing allele frequencies from whole exome sequencing for 60,706 unrelated individuals lacking Mendelian pediatric disease, has been used to estimate the probability that any single gene is intolerant to LoF mutations (known as pLI) (Lek et al., 2016). We compared the distribution of probabilities for a random sample of all genes (for ease of plotting) to RP genes and known DBA genes. Mann-Whitney-U tests were used to determine if there were significant differences in pLI between groups.

Analysis of Mass Spectrometry Data—Data extraction and searching was done using Spectrum Mill MS Proteomics Workbench v6.0 pre-release software package (Agilent Technologies). All extracted spectra were searched against a UniProt database containing human reference proteome sequences. Search was done using parent and fragment mass tolerance of 20ppm, and enzyme specificity set to trypsin allow P with 4 missed cleavages.

Cysteine carbamidomethylation and TMT labeling at lysine and N-termini were set as fixed modifications. Allowed variable modifications were acetylation of protein N-termini, oxidized methionine, deamidation of asparagine, pyro-glutamic acid at peptide N-terminal glutamine, and pyro-carbamidomethylation at peptide N-terminal cysteine. Autovalidation was performed at peptide level with set FDR of less than 0.8 for charges 2 to 4, and less than 0.4 for charge 5 followed by protein level with set protein FDR of 0. Subgroup specific grouping of proteins was used for generating final protein table for each of the TMT experiments, which ensures that only peptides specific to a particular isoform are used for quantitation. Reporter ion intensities were corrected for isotopic impurities in the Spectrum Mill protein/peptide summary module using the static correction method and correction factors obtained from the reagent manufacturer's certificate of analysis (<https://www.thermofisher.com/order/catalog/product/90406>) for lot number QE214905A.

Only ribosomal proteins with 2 or more distinct peptides were used for further analysis of the data. For each TMT experiment representing one of the ribosomal fractions the normalized expression for protein i in TMT channel j is calculated using the following equation:

$$\frac{I_i}{\sum_{K \in RP} I_K} \times \frac{T_j}{\sum_{t=1}^9 T_t} \times \frac{\#O}{\#A}$$

Where I = protein precursor intensity, i = protein, RP = ribosomal proteins, T = TMT channel abundance for a given protein, j = TMT channel, $\#O$ = number of observed peptides for a protein, $\#A$ = number of theoretical peptides for a protein. The first term represents fractional precursor intensity over all observed ribosomal proteins; the second term is the fractional TMT reporter intensity and the final term adjusts for protein length. All normalized values were then \log_2 transformed and median centered for each TMT channel. These values were used for all subsequent statistical analyses. Standard linear regression was performed between groups (shLuc, shRPL5, shRPS19, shTSR2) for different fractions (M, LP, HP) and for different subunits (80S, 60S, 40S). Linear fits and Pearson correlation coefficients are reported. Studentized, or jack-knifed, residuals were calculated in R using the `studres()` function in the MASS R package.

The ribosome-associated proteins were analyzed by identifying proteins that were similarly abundant as RPs in fractions of actively translating polysomes (LP and HP) in controls or cells with ribosomal perturbations. To do so, we have plotted intensity/density profiles for the HP/LP samples, in which we noted that the density (a smoothed histogram) was bimodal. We then used a mixture model, which essentially clustered the proteins into two groups - one RP-like and the other containing the remaining proteins. If a protein was in this RP-like cluster for any HP/LP sample, it was included in the analysis. In total, we identified 227 proteins (excluding the RPs) that fell into this cluster.

Analysis of RNA and Ribosome Profiling Libraries—Raw reads were trimmed using cutadapt with the options “-q 5 -m 20 --discard-untrimmed -a AGATCGGAAGAGCACACGTCTG” (<https://cutadapt.readthedocs.io/en/stable/>). Bowtie2

was then used to align trimmed reads to rRNA, tRNA, and abundant noncoding RNAs (<http://bowtie-bio.sourceforge.net/bowtie2/index.shtml>). FASTQC (<http://www.bioinformatics.babraham.ac.uk/projects/fastqc>) was used to determine that adapters and other sequences had been removed and to calculate the fragment length distribution of RPFs. The remaining reads were then aligned to the human hg19 genome build allowing for junctions based upon ENSEMBL transcripts using Tophat with the options “--no-novel-juncs --library-type fr-unstranded” (<http://ccb.jhu.edu/software/tophat/index.shtml>). Non-uniquely mapping reads were excluded using Samtools (<http://samtools.sourceforge.net>). RSeQC was used to determine the percentage of reads mapping to 5' UTRs, CDS, and 3' UTRs (<http://rseqc.sourceforge.net>). Triplet periodicity was assessed using RibORF (<https://personal.broadinstitute.org/zheji/software/RibORF.html>). For RNA-seq, genes were quantified either using Cuffquant and Cuffnorm with the option “-max-bundle-frags 20000000” or using HTSeq-count in intersection-strict mode. Fragments per kilobase per million (FPKM) were subsequently transformed to transcripts per million (TPM). For RPFs, reads between 26 and 34 nucleotides in length were quantified in the CDSs of protein coding genes using HTSeq-count. Reads mapping to less than 45 nucleotides from the start codon or 15 nucleotides from the stop codon were not included in order to reduce read biases in the 5' and 3' ends of CDSs. To determine differentially expressed genes between control and RPH or TSR2 suppression conditions, we used a negative binomial model (mean and variance of distribution estimated in DESeq2) (<http://bioconductor.org/packages/devel/bioc/vignettes/DESeq2/inst/doc/DESeq2.html>). To determine differentially translated (e.g. changes in TE) genes, we used Xtail (<https://github.com/xryanglab/xtail>), which first uses the negative binomial distribution to estimate either (1) the \log_2 fold changes separately for mRNAs and RPFs between conditions (i.e. mRNA and RPF) or (2) the \log_2 fold changes for mRNA to RPF within conditions (i.e. TE_{control} and TE_{RPH}), and then estimates a discrete joint probability distribution of either (1) mRNA and RPF or (2) TE_{control} and TE_{RPH} . Testing of differential translation (i.e. TE in both cases) was then performed, the least significant result of the two methods was kept. The Benjamini–Hochberg FDR was used to control for multiple testing. Only genes with >150 mRNA counts and >90 RPF counts were analyzed in order to obtain more stable estimates of TE. Gene set enrichment analysis (GSEA) was used with the “Preranked” option and 10,000 permutations for TE or mRNA. An erythroid gene set was derived by taking all genes that were > 4 \log_2 fold up-regulated between CD34+ and pro-erythroblast stages of normal human erythropoiesis. In addition, BIOCARTA, KEGG, and REACTOME canonical pathways were investigated.

Re-Annotation of 5' UTRs—Because the TSS of a gene can vary between cell types and is often misannotated, we used cap analysis of gene expression (CAGE) data from K562 cells to define empirical TSS locations at 10-bp resolution using a heuristic algorithm. Four replicates of CAGE data (aligned BAM files CNhs12334.10824-111C5, CNhs12335.10825-111C6, CNhs12336.10826-111C7, and CNhs11250.10454-106G4) were downloaded from the FANTOM project (Arner et al., 2015) and merged using samtools. Each Ensembl gene (+/- 1 kb around the annotated ends of the gene) was scanned at 20-bp resolution to find the 100-bp window with the most number of CAGE reads, considering strand. Additional windows were chosen until either the windows either contained 80% of the total reads overlapping the gene or until these windows, upon merging of overlapping

regions, contained 500bp of sequence. The top region was further scanned to find the 10-bp window with the most number of reads. This 10-bp window was defined as the empirical TSS. Next, empirical 5' UTRs were determined by overlapping empirical TSSs with annotated ENSEMBL 5' UTR positions for each transcript. When the empirical TSS fell within the annotated 5' UTR, the 5' UTR was shortened to start at the empirical TSS. When the empirical TSS was upstream of the annotated 5' UTR, the 5' UTR was extended to the empirical TSS. In all cases, the shortest 5' UTR for a gene across all transcripts was taken, genes without empirical TSSs were excluded, and only genes with empirical 5' UTRs <500 nucleotides were included. Manual investigation of genes with 5' UTRs >500 nucleotides revealed that the majority of these were false positives that often had weak CAGE signal and/or poor initial annotations. Additionally, CD34⁺ HSPC CAGE data was downloaded from the ENCODE project (ENCFF000TTH.bam). For the 36 hematopoietic TFs investigated in CD34⁺ CAGE, single nucleotide TSSs were identified based upon the strongest CAGE signal at any single nucleotide.

Analysis of Features for Association with TE—A number of features were investigated for differences between RPH-sensitive and unchanged genes. The complexity of the empirical 5' UTR secondary structure was determined using RNAfold (<http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi>). Gene expression during erythropoiesis was performed by An et al. (An et al., 2014) and Li et al. (Li et al., 2014) and processed as previously described (Ulirsch et al., 2016). Protein abundances for erythroid progenitors (“prog2”) were obtained from Gautier et al. (Gautier et al., 2016). ORF lengths were calculated for the most abundant transcript (determined by highest TPM from Cuffnorm) for each gene using the GenomicRanges R package. Gene essentiality scores for the erythroid K562 cell line were obtained from the CRISPR screen performed by Wang et al. (Wang et al., 2015). As the key erythroid transcription factor GATA1 was the most K562-specific essential gene (compared to 3 other chronic myelogenous leukemia cell lines), we determined that the essentiality scores in K562 cells were likely relevant to our primary human erythroid cells. A random forest model was used to determine the percentage of variation in gene expression using mRNA, shLuc mRNA expression, shLuc TE, CDS length, 5' UTR length, 5' UTR complexity (G), uAUG presence, and TOP-like motif presence. The random forest was trained on 3,000 genes with measurements for all characteristics and results are reported from the held out set of 618 genes. The R package randomForest was used with the parameters “mtry=3, mtree=200, ntree=501”.

Motif Analyses—First, we investigated whether TOP or TOP-like motifs were present within the first 20 nucleotides of the empirical 5' UTR by matching the strings C(C|U){6} (Thoreen et al., 2012) or (C|U){3}U(C|U){3} (Hsieh et al., 2012). Although we saw an enrichment for TOP-like motifs in RPH-sensitive transcripts, this motif was not present in the majority of transcripts, so we performed a global *de novo* motif analysis of 5' UTRs (restricted to 30 nucleotides at the 5' end, 30 nucleotides at the 3' end, and across the entire 5' UTR) using Homer with standard options except for “-rna” (<http://homer.ucsd.edu/homer/>). Next, we took an alternative approach and trained a gapped k-mer support vector machine (SVM) to try to separate RPH-sensitive transcripts from unchanged transcripts

based upon the presence of kmers of length 6, 8, or 10 in the corresponding 5' UTRs using 5-fold cross validation.

Bone Marrow Biopsy Section Immunohistochemical Staining and Analysis—

For each of seven different DBA patients and three normal healthy controls, bone marrow biopsy sections were immunohistochemically stained for GATA1, as previously described (Lee et al., 2017). All sections were stained and imaged together to ensure consistency between samples. Several independent images from each stained sample were segmented and quantified in CellProfiler (Carpenter et al., 2006). In brief, nuclei were segmented by blue intensity and filtered for Hue to retain only brown staining GATA1 positive cells, which we manually confirmed were entirely composed of erythroid cells. We excluded large megakaryocytes by the segmentation procedure. Measurements of intensity and morphological properties were quantified for every cell. Python was used to analyze cellular features, and the Mann-Whitney U non-parametric test was used to estimate the significance of differences observed between DBA and normal cells.

Statistical Analyses—All pairwise comparisons were assessed using an unpaired two-tailed Student's *t*-test, unless otherwise indicated in the main text or in the figure legends. Results were considered significant if the *P* value was <0.05.

DATA AND SOFTWARE AVAILABILITY

Accession Codes—The raw mass spectrometry data have been deposited in the public proteomics repository MassIVE: MSV000080283.

The RNA-seq and ribosome profiling data reported in this manuscript are deposited in the Gene Expression Omnibus (GEO) data repository: GSE89183.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank D. Nathan, S. Orkin, L. Zon, K. Patel, S. Eichhorn, Z. Ji, J. Clohessy, and Sankaran laboratory members for valuable discussions. R.K.K received partial support from a Boehringer Ingelheim MD Fellowship. S.K.M. received support from National Institutes of Health (NIH) Grant T32 HL007574. V.G.P. received support from the Swiss National Science Foundation, Novartis Foundation, Olga Mayenfisch Stiftung, and the European Research Council (EURIBIO260676). This work was supported by NIH Grants R01 DK103794 and R33 HL120791, as well as a DBA Foundation and March of Dimes Basil O'Connor Scholar Award (to V.G.S.).

References

- Allam R, Chennupati V, Veiga DFT, Maslowski KM, Tardivel A, Quadroni M, Duchosal M, MacDonald HR, Fasel N, Angelillo-Scherrer A, et al. An Unexpected Role for Ribonuclease Inhibitor (RNH1) in Erythropoiesis. *Blood*. 2014; 124:244–244.
- An X, Schulz VP, Li J, Wu K, Liu J, Xue F, Hu J, Mohandas N, Gallagher PG. Global transcriptome analyses of human and murine terminal erythroid differentiation. *Blood*. 2014; 123:3466–3477. [PubMed: 24637361]

- Arner E, Daub CO, Vitting-Seerup K, Andersson R, Lilje B, Drablos F, Lennartsson A, Ronnerblad M, Hyrdziusko O, Vitezic M, et al. Transcribed enhancers lead waves of coordinated transcription in transitioning mammalian cells. *Science*. 2015; 347:1010–1014. [PubMed: 25678556]
- Bolze A, Mahlaoui N, Byun M, Turner B, Trede N, Ellis SR, Abhyankar A, Itan Y, Patin E, Brebner S, et al. Ribosomal protein SA haploinsufficiency in humans with isolated congenital asplenia. *Science*. 2013; 340:976–978. [PubMed: 23579497]
- Brooks SS, Wall AL, Golzio C, Reid DW, Kondyles A, Willer JR, Botti C, Nicchitta CV, Katsanis N, Davis EE. A novel ribosomopathy caused by dysfunction of RPL10 disrupts neurodevelopment and causes X-linked microcephaly in humans. *Genetics*. 2014; 198:723–733. [PubMed: 25316788]
- Buszczak M, Signer RA, Morrison SJ. Cellular differences in protein synthesis regulate tissue homeostasis. *Cell*. 2014; 159:242–251. [PubMed: 25303523]
- Bywater MJ, Poortinga G, Sanij E, Hein N, Peck A, Cullinane C, Wall M, Cluse L, Drygin D, Andres K, et al. Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. *Cancer cell*. 2012; 22:51–65. [PubMed: 22789538]
- Carpenter AE, Jones TR, Lamprecht MR, Clarke C, Kang IH, Friman O, Guertin DA, Chang JH, Lindquist RA, Moffat J, et al. CellProfiler: image analysis software for identifying and quantifying cell phenotypes. *Genome biology*. 2006; 7:R100. [PubMed: 17076895]
- Casanova JL, Conley ME, Seligman SJ, Abel L, Notarangelo LD. Guidelines for genetic studies in single patients: lessons from primary immunodeficiencies. *The Journal of experimental medicine*. 2014; 211:2137–2149. [PubMed: 25311508]
- Doulatov S, Notta F, Laurenti E, Dick JE. Hematopoiesis: a human perspective. *Cell stem cell*. 2012; 10:120–136. [PubMed: 22305562]
- Engreitz JM, Pandya-Jones A, McDonel P, Shishkin A, Sirokman K, Surka C, Kadri S, Xing J, Goren A, Lander ES, et al. The Xist lncRNA exploits three-dimensional genome architecture to spread across the X chromosome. *Science*. 2013; 341:1237973. [PubMed: 23828888]
- Farrar JE, Quarello P, Fisher R, O'Brien KA, Aspesi A, Parrella S, Henson AL, Seidel NE, Atsidaftos E, Prakash S, et al. Exploiting pre-rRNA processing in Diamond Blackfan anemia gene discovery and diagnosis. *Am J Hematol*. 2014; 89:985–991. [PubMed: 25042156]
- Gautier EF, Ducamp S, Leduc M, Salnot V, Guillonnet F, Dussiot M, Hale J, Giarratana MC, Raimbault A, Douay L, et al. Comprehensive Proteomic Analysis of Human Erythropoiesis. *Cell reports*. 2016; 16:1470–1484. [PubMed: 27452463]
- Gazda HT, Sheen MR, Vlachos A, Choesmel V, O'Donohue MF, Schneider H, Darras N, Hasman C, Sieff CA, Newburger PE, et al. Ribosomal protein L5 and L11 mutations are associated with cleft palate and abnormal thumbs in Diamond-Blackfan anemia patients. *Am J Hum Genet*. 2008; 83:769–780. [PubMed: 19061985]
- Giani FC, Fiorini C, Wakabayashi A, Ludwig LS, Salem RM, Jobaliya CD, Regan SN, Ulirsch JC, Liang G, Steinberg-Shemer O, et al. Targeted Application of Human Genetic Variation Can Improve Red Blood Cell Production from Stem Cells. *Cell Stem Cell*. 2016; 18:73–78. [PubMed: 26607381]
- Gripp KW, Curry C, Olney AH, Sandoval C, Fisher J, Chong JX, Pilchman L, Sahraoui R, Stabley DL, et al. Genomics UW.C.f.M. Diamond-Blackfan anemia with mandibulofacial dystostosis is heterogeneous, including the novel DBA genes TSR2 and RPS28. *Am J Med Genet A*. 2014; 164A:2240–2249. [PubMed: 24942156]
- Henras AK, Plisson-Chastang C, O'Donohue MF, Chakraborty A, Gleizes PE. An overview of pre-ribosomal RNA processing in eukaryotes. *Wiley Interdiscip Rev RNA*. 2015; 6:225–242. [PubMed: 25346433]
- Hinnebusch AG, Ivanov IP, Sonenberg N. Translational control by 5'-untranslated regions of eukaryotic mRNAs. *Science*. 2016; 352:1413–1416. [PubMed: 27313038]
- Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, Shi EY, Stumpf CR, Christensen C, Bonham MJ, et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. *Nature*. 2012; 485:55–61. [PubMed: 22367541]
- Ingolia NT. Ribosome Footprint Profiling of Translation throughout the Genome. *Cell*. 2016; 165:22–33. [PubMed: 27015305]

- Iskander D, Psaila B, Gerrard G, Chaidos A, En Foong H, Harrington Y, Karnik LC, Roberts I, de la Fuente J, Karadimitris A. Elucidation of the EP defect in Diamond-Blackfan anemia by characterization and prospective isolation of human EPs. *Blood*. 2015; 125:2553–2557. [PubMed: 25755292]
- Jovanovic M, Rooney MS, Mertins P, Przybylski D, Chevrier N, Satija R, Rodriguez EH, Fields AP, Schwartz S, Raychowdhury R, et al. Immunogenetics. Dynamic profiling of the protein life cycle in response to pathogens. *Science*. 2015; 347:1259038. [PubMed: 25745177]
- Khatter H, Myasnikov AG, Natchiar SK, Klaholz BP. Structure of the human 80S ribosome. *Nature*. 2015; 520:640–645. [PubMed: 25901680]
- Kim AR, Ulirsch JC, Wilmes S, Unal E, Moraga I, Karakukcu M, Yuan D, Kazerounian S, Abdulhay NJ, King DS, et al. Functional Selectivity in Cytokine Signaling Revealed Through a Pathogenic EPO Mutation. *Cell*. 2017; 168:1053–1064. e1015. [PubMed: 28283061]
- Lee WY, Weinberg OK, Pinkus GS. GATA1 Is a Sensitive and Specific Nuclear Marker for Erythroid and Megakaryocytic Lineages. *Am J Clin Pathol*. 2017; 147:420–426. [PubMed: 28340113]
- Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, O'Donnell-Luria AH, Ware JS, Hill AJ, Cummings BB, et al. Analysis of protein-coding genetic variation in 60,706 humans. *Nature*. 2016; 536:285–291. [PubMed: 27535533]
- Li J, Hale J, Bhagia P, Xue F, Chen L, Jaffray J, Yan H, Lane J, Gallagher PG, Mohandas N, et al. Isolation and transcriptome analyses of human erythroid progenitors: BFU-E and CFU-E. *Blood*. 2014; 124:3636–3645. [PubMed: 25339359]
- Ludwig LS, Gazda HT, Eng JC, Eichhorn SW, Thiru P, Ghazvinian R, George TI, Gotlib JR, Beggs AH, Sieff CA, et al. Altered translation of GATA1 in Diamond-Blackfan anemia. *Nature medicine*. 2014; 20:748–753.
- McCann KL, Baserga SJ. Genetics. Mysterious ribosomopathies. *Science*. 2013; 341:849–850. [PubMed: 23970686]
- Mills EW, Wangen J, Green R, Ingolia NT. Dynamic Regulation of a Ribosome Rescue Pathway in Erythroid Cells and Platelets. *Cell reports*. 2016; 17:1–10. [PubMed: 27681415]
- Mirabello L, Khincha PP, Ellis SR, Giri N, Brodie S, Chandrasekharappa SC, Donovan FX, Zhou W, Hicks BD, Boland JF, et al. Novel and known ribosomal causes of Diamond-Blackfan anaemia identified through comprehensive genomic characterisation. *Journal of medical genetics*. 2017; 54:417–425. [PubMed: 28280134]
- Nathan DG, Clarke BJ, Hillman DG, Alter BP, Housman DE. Erythroid precursors in congenital hypoplastic (Diamond-Blackfan) anemia. *The Journal of clinical investigation*. 1978; 61:489–498. [PubMed: 621285]
- Notta F, Zandi S, Takayama N, Dobson S, Gan OI, Wilson G, Kaufmann KB, McLeod J, Laurenti E, Dunant CF, et al. Distinct routes of lineage development reshape the human blood hierarchy across ontogeny. *Science*. 2016; 351:aab2116. [PubMed: 26541609]
- Ohene-Abuakwa Y, Orfali KA, Marius C, Ball SE. Two-phase culture in Diamond Blackfan anemia: localization of erythroid defect. *Blood*. 2005; 105:838–846. [PubMed: 15238419]
- Orkin SH, Zon LI. Hematopoiesis: an evolving paradigm for stem cell biology. *Cell*. 2008; 132:631–644. [PubMed: 18295580]
- Paul F, Arkin Y, Giladi A, Jaitin DA, Kenigsberg E, Keren-Shaul H, Winter D, Lara-Astiaso D, Gury M, Weiner A, et al. Transcriptional Heterogeneity and Lineage Commitment in Myeloid Progenitors. *Cell*. 2015; 163:1663–1677. [PubMed: 26627738]
- Perie L, Duffy KR, Kok L, de Boer RJ, Schumacher TN. The Branching Point in Erythro-Myeloid Differentiation. *Cell*. 2015; 163:1655–1662. [PubMed: 26687356]
- Preti M, O'Donohue MF, Montel-Lehry N, Bortolin-Cavaille ML, Choemmel V, Gleizes PE. Gradual processing of the ITS1 from the nucleolus to the cytoplasm during synthesis of the human 18S rRNA. *Nucleic Acids Res*. 2013; 41:4709–4723. [PubMed: 23482395]
- Reschke M, Clohessy JG, Seitzer N, Goldstein DP, Breitkopf SB, Schmolze DB, Ala U, Asara JM, Beck AH, Pandolfi PP. Characterization and analysis of the composition and dynamics of the mammalian riboproteome. *Cell reports*. 2013; 4:1276–1287. [PubMed: 24055062]

- Robledo S, Idol RA, Crimmins DL, Ladenson JH, Mason PJ, Bessler M. The role of human ribosomal proteins in the maturation of rRNA and ribosome production. *Rna*. 2008; 14:1918–1929. [PubMed: 18697920]
- Roepcke S, Zhi D, Vingron M, Arndt PF. Identification of highly specific localized sequence motifs in human ribosomal protein gene promoters. *Gene*. 2006; 365:48–56. [PubMed: 16343812]
- Sankaran VG, Ghazvinian R, Do R, Thiru P, Vergilio JA, Beggs AH, Sieff CA, Orkin SH, Nathan DG, Lander ES, et al. Exome sequencing identifies GATA1 mutations resulting in Diamond-Blackfan anemia. *The Journal of clinical investigation*. 2012; 122:2439–2443. [PubMed: 22706301]
- Sankaran VG, Weiss MJ. Anemia: progress in molecular mechanisms and therapies. *Nature medicine*. 2015; 21:221–230.
- Schutz S, Fischer U, Altvater M, Nerurkar P, Pena C, Gerber M, Chang Y, Caesar S, Schubert OT, Schlenstedt G, et al. A RanGTP-independent mechanism allows ribosomal protein nuclear import for ribosome assembly. *Elife*. 2014; 3:e03473. [PubMed: 25144938]
- Schwanhauser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, Chen W, Selbach M. Global quantification of mammalian gene expression control. *Nature*. 2011; 473:337–342. [PubMed: 21593866]
- Shah P, Ding Y, Niemczyk M, Kudla G, Plotkin JB. Rate-limiting steps in yeast protein translation. *Cell*. 2013; 153:1589–1601. [PubMed: 23791185]
- Shi Z, Fujii K, Kovary KM, Genuth NR, Rost HL, Teruel MN, Barna M. Heterogeneous Ribosomes Preferentially Translate Distinct Subpools of mRNAs Genome-wide. *Molecular cell*. 2017; 67:71–83. e77. [PubMed: 28625553]
- Signer RA, Magee JA, Salic A, Morrison SJ. Haematopoietic stem cells require a highly regulated protein synthesis rate. *Nature*. 2014; 509:49–54. [PubMed: 24670665]
- Srivastava D, DeWitt N. In Vivo Cellular Reprogramming: The Next Generation. *Cell*. 2016; 166:1386–1396. [PubMed: 27610565]
- Sung MK, Porras-Yakushi TR, Reitsma JM, Huber FM, Sweredoski MJ, Hoelz A, Hess S, Deshaies RJ. A conserved quality-control pathway that mediates degradation of unassembled ribosomal proteins. *eLife*. 2016;5.
- Tanay A, Regev A. Scaling single-cell genomics from phenomenology to mechanism. *Nature*. 2017; 541:331–338. [PubMed: 28102262]
- Thompson MK, Rojas-Duran MF, Gangaramani P, Gilbert WV. The ribosomal protein Asc1/RACK1 is required for efficient translation of short mRNAs. *eLife*. 2016;5.
- Thoreen CC, Chantranupong L, Keys HR, Wang T, Gray NS, Sabatini DM. A unifying model for mTORC1-mediated regulation of mRNA translation. *Nature*. 2012; 485:109–113. [PubMed: 22552098]
- Ulirsch JC, Nandakumar SK, Wang L, Giani FC, Zhang X, Rogov P, Melnikov A, McDonel P, Do R, Mikkelsen TS, et al. Systematic Functional Dissection of Common Genetic Variation Affecting Red Blood Cell Traits. *Cell*. 2016; 165:1530–1545. [PubMed: 27259154]
- van Galen P, Kreso A, Mbong N, Kent DG, Fitzmaurice T, Chambers JE, Xie S, Laurenti E, Hermans K, Eppert K, et al. The unfolded protein response governs integrity of the haematopoietic stem-cell pool during stress. *Nature*. 2014; 510:268–272. [PubMed: 24776803]
- Velten L, Haas SF, Raffel S, Blaszkiewicz S, Islam S, Hennig BP, Hirche C, Lutz C, Buss EC, Nowak D, et al. Human haematopoietic stem cell lineage commitment is a continuous process. *Nat Cell Biol*. 2017; 19:271–281. [PubMed: 28319093]
- Wang T, Birsoy K, Hughes NW, Krupczak KM, Post Y, Wei JJ, Lander ES, Sabatini DM. Identification and characterization of essential genes in the human genome. *Science*. 2015; 350:1096–1101. [PubMed: 26472758]
- Weiss MJ, Yu C, Orkin SH. Erythroid-cell-specific properties of transcription factor GATA-1 revealed by phenotypic rescue of a gene-targeted cell line. *Molecular and cellular biology*. 1997; 17:1642–1651. [PubMed: 9032291]

HIGHLIGHTS

- Molecular lesions underlying DBA reduce ribosome levels in hematopoietic cells
- Ribosome composition remains constant in cells with DBA-associated lesions
- Reduced ribosome levels selectively impair translation of a subset of mRNAs
- Translational perturbations in DBA impair lineage-commitment in HSPCs




Figure 1. DBA with TSR2 Loss of Function

(A) Identification of a missense mutation in TSR2 in a pedigree with two affected male cousins.

(B) The human TSR2 ortholog could substantially rescue growth of the *Tsr2* depleted yeast strain, while the TSR2 ortholog with the DBA-associated mutation had reduced rescue.

(C) Western blot showing the identification of two short hairpin RNAs (shRNAs) that target TSR2 in primary human HSPCs undergoing erythroid lineage commitment on day 5 after transduction.

(D) The ratio of erythroid (CD235a⁺) to non-erythroid (CD235a⁻) cells on day 5 in differentiating HSPCs after transduction with shRNAs targeting Luciferase (shLuc) or TSR2 (shTSR2). The data are shown as the mean ± the standard error of mean (SEM) from three independent experiments. (**P < 0.01 using an unpaired two-tailed Student’s t-test).

(E) Western blot detection of GATA1 protein from lysates of differentiating HSPCs on day 5 after transduction. Arrowheads indicate GATA1 full length (FL) and GATA1 short, respectively, on top and bottom.

(F) *GATA1* mRNA levels derived from mRNA-seq in differentiating HSPCs. Shown is the mean ± standard deviation (SD) of two biological replicates.

(G) The ratio of erythroid (CD235a⁺) to non-erythroid (CD235a⁻) cells on day 5 after transduction with shTSR2 and either a control vector or with GATA1 rescue. Shown is the mean \pm the SD from three independent experiments. (****P 0.0001 using an unpaired two-tailed Student's t-test).

(H) Quantitative RT-PCR gene expression (normalized to β -actin) in differentiating HSPCs upon TSR2 suppression with or without GATA1 rescue. Shown is the mean \pm the SD of three replicates. (**P 0.01; ***P 0.001; ****P 0.0001 using an unpaired two-tailed Student's t-test).

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 2. DBA-Associated Molecular Lesions Result in Reduced Ribosome Levels

(A) TSR2 suppression results in impaired pre-rRNA processing in human hematopoietic cells. Ethidium bromide-stained RNA gel (left panel) and Northern blot analysis (right panel) are shown in setting of TSR2 suppression.

(B) Western blot detection of the indicated proteins from lysates of differentiating HSPCs following TSR2 suppression.

(C) Relative quantification of RP intensities normalized to GAPDH.

(D) Polysome profiles of primary human HSPCs undergoing differentiation that show the reduction of monosome and polysome levels with DBA-associated molecular lesions. The

traces are shown offset from one another on the arbitrary y-axis (derived from relative absorbance at 254 nm) for ease of visualization.

(E–F) Relative quantification of monosome and polysome abundances from primary human HSPCs undergoing erythroid differentiation. Shown is the mean \pm SD of two independent experiments. (*P 0.05; **P 0.01; ***P 0.001 using an unpaired two-tailed Student's t-test).

(G) Absolute numbers of erythroid cells as measured by surface marker expression of CD235a and myeloid cells as measured by CD41a or CD11b at 72 h after treatment with increasing concentrations of the RNA polymerase I inhibitor CX-5461 in primary human HSPCs undergoing differentiation. Results from a representative experiment are shown. (H) Western blot detection of the indicated proteins from lysates of differentiating HSPCs at 72 h after treatment with increasing concentrations of CX-5461.




Figure 3. No Evidence for Variation in Ribosome Protein Composition in Cells with DBA-Associated Molecular Lesions

(A) Human hematopoietic cells treated with control vectors or with TSR2, RPS19, or RPL5 suppression were fractionated by sucrose gradient sedimentation. Monosome fractions (M), light polysomes (LP), and heavy polysomes (HP) were analyzed by tandem mass tag (TMT) mass spectrometry.

(B–D) Log₂ transformed and median centered RP intensities from two independent replicates in various knockdown (KD) conditions versus shLuc control in HP, LP, and M fractions. RPs of the large subunit are shown in blue, RPs of the small subunit are shown in black, and the targeted or related RP is highlighted in red. Linear regressions for small subunit RPs (black), large subunit RPs (blue) and all RPs together (grey) are shown and Pearson correlations are reported.




Figure 4. Identification of Transcripts Whose Translation Is Sensitive to RP Haploinsufficiency

(A) After adapter trimming and rRNA removal, the distribution of ribosome profiling reads is shown. The reads all fall between 27–32 nucleotides.

(B) The ribosome profiling data exhibit triplet periodicity based upon meta-gene analysis of CDS regions. A representative example is shown.

(C) Differences between shLuc and shRPL5 or shRPS19 in primary differentiating human HSPCs are highly correlated at both the transcriptional and translational levels, as displayed in a scatter plot where color indicates point density. Both local regression (with confidence intervals) and linear fits are shown in red. Pearson correlations are indicated.

(D) Venn diagrams of differentially expressed (Δ mRNA, FDR < 1% and \log_2 |fold change| > 1) or differentially translated (Δ translation efficiency (TE), FDR < 10%) genes showing

that changes in translation and in transcription resulting from RP haploinsufficiency compared to control occur largely independent of each other.

(E) Gene set enrichment analyses indicate that RP genes are co-regulated at the translational (permutation FDR < 0.0001), but not transcriptional (permutation FDR = 0.36) level with RP haploinsufficiency. The enrichment score is plotted in green, and genes are plotted as black lines according to their rank.

(F) The relative reduction in translation efficiency for selected RP haploinsufficiency-sensitive transcripts including GATA1 is shown in green, relative changes in mRNA expression are shown in red.

(G) Boxplots for CDS length or cellular protein intensities in primary human erythroid progenitors are shown across FDR thresholds for differential translation. CDS length was calculated for the most abundant transcript in shLuc and RP haploinsufficient differentiating HSPCs (*controlled for PolyA-selection based bias). P-values were determined by an F-test.




Figure 5. Analysis of 5' UTR Features of Key Hematopoietic Transcription Factors

(A) Boxplots for different 5' UTR features are shown across FDR thresholds for differential translation in primary differentiating human HSPCs. The minimum free energy (ΔG) was calculated using RNAfold for the entire 5' UTR. As this prediction is correlated with length, ΔG corrected for 5' UTR length was also analyzed. P-values were determined by an F-test. (B) Master regulator transcription factors (TFs) are shown in their approximate positions of action in a model of hematopoiesis. HSC: hematopoietic stem cell, RBCs: red blood cells, Mega: megakaryocyte, Gran: granulocyte, Mono: monocyte, B Lymph: B lymphocyte, T Lymph: T lymphocyte, NK: natural killer cell.

(C–D) The GATA1 5' UTR is shorter and less structured than those of most other hematopoietic master TFs. GATA1 is highlighted in red. The median line for the 10% FDR RP haploinsufficiency-sensitive transcripts is indicated, respectively.

(E–F) Most hematopoietic master TFs have significantly longer (2.5 mean-fold difference) and more structured 5' UTRs (2.8 mean-fold difference in G) than transcripts that are translationally downregulated with RP haploinsufficiency.

(G) Normalized baseline translation efficiencies (TE) based on ribosome profiling in unperturbed HSPCs undergoing erythroid lineage commitment are shown for GATA1, RUNX1, LMO2, and ETV6.

(H) Histogram plots for Ter119 in GFP⁺ populations derived from G1E cells that were transduced with GATA1-, RUNX1-, LMO2- or ETV6-5'UTR-GATA1 cDNA constructs. The mean \pm the SD for the percentages of Ter119⁺ cells of three replicates is shown.

(I) Bar graphs for normalized ratios of % Ter119⁺ populations in GFP⁺ cells/ *GATA1* mRNA levels from G1E cells that were transduced with GATA1-, RUNX1-, LMO2- or ETV6-5'UTR-GATA1 constructs. The mean \pm the SD of three replicates is shown (****P 0.0001 using an unpaired two-tailed Student's t-test).

(J) Bar graphs for normalized ratios of the Ter119 mean fluorescence intensities (MFIs) of GFP⁺ cells/*GATA1* mRNA levels from G1E cells that were transduced with the constructs listed above. The mean \pm the SD of three replicates is shown (****P 0.0001 using an unpaired two-tailed Student's t-test).




Figure 6. Reduced GATA1 Protein Levels in Bone Marrow Progenitors from DBA Patients
 Representative images of human bone marrow biopsies stained for GATA1 protein (brown) in DBA patients with diverse RP mutations and normal healthy controls. Below, is a density plot comparing single cell saturation intensities between DBA patients and normal individuals that shows significantly reduced expression in DBA (n = 2759 for DBA and 2149 cells for controls; significance calculated by the Mann-Whitney U test).




Figure 7. Reduced GATA1 Protein Expression in Primary HSPCs from DBA Patients
 (A) Intracellular flow cytometric detection shows low levels of GATA1 expression in a subset of both the primitive CD34⁺CD38⁻ and more differentiated CD34⁺CD38⁺ HSPC populations (left panels). With differentiation, robust and high-level GATA1 protein expression can be seen in committed CD235a⁺CD71⁺ erythroid cells (right panels).
 (B) Reduced GATA1 protein expression in single cells from HSPC populations from a DBA patient bone marrow aspirate sample compared to a healthy control.
 (C) GATA1 MFIs show a consistent reduction in GATA1 expression in CD34⁺CD38⁻ and CD34⁺CD38⁺ HSPC populations in DBA patients with *RPL35A*, *RPL5*, or *RPS19* mutations compared to healthy controls.

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Goat polyclonal anti-GATA1 (M-20)	Santa Cruz Biotechnology	Cat#: sc-1234; RRID: AB_2263157
Rabbit polyclonal anti-TSR2	Abcam	Cat#: ab155810; RRID: AB_2715561
Mouse monoclonal anti-RPS19 (WW-4)	Santa Cruz Biotechnology	Cat#: sc-100836; RRID: AB_1129199
Goat polyclonal anti-RPL5 (D-20)	Santa Cruz Biotechnology	Cat#: sc-103865; RRID: AB_2182039
Goat polyclonal anti-RPL11 (N-17)	Santa Cruz Biotechnology	Cat#: sc-25931; RRID: AB_2181298
Goat polyclonal anti-RPS20 (G-15)	Santa Cruz Biotechnology	Cat#: sc-55035; RRID: AB_2180344
Rabbit polyclonal anti-RPS24	Abcam	Cat#: ab102986; RRID: AB_10711571
Rabbit polyclonal anti-RPS26	Abcam	Cat#: ab104050; RRID: AB_10710999
Rabbit polyclonal anti-RPSA	Abcam	Cat#: ab137388; RRID: AB_2715562
Rabbit polyclonal anti-RPL28 (FL-137)	Santa Cruz Biotechnology	Cat#: sc-50362; RRID: AB_2181746
Rabbit polyclonal anti-EPOR (M-20)	Santa Cruz Biotechnology	Cat#: sc-697; RRID: AB_631468
Rabbit polyclonal anti-STAT5A (C-17)	Santa Cruz Biotechnology	Cat#: sc-835; RRID: AB_632446
Rabbit polyclonal anti-JAK2 (HR-758)	Santa Cruz Biotechnology	Cat#: sc-278; RRID: AB_631853
Mouse monoclonal anti-BYSTIN (A-10)	Santa Cruz Biotechnology	Cat#: sc-271722; RRID: AB_10707663
Goat polyclonal anti-LAMIN B (C-20)	Santa Cruz Biotechnology	Cat#: sc-6216; RRID: AB_648156
Mouse monoclonal anti-GAPDH (6C5)	Santa Cruz Biotechnology	Cat#: sc-32233; RRID: AB_627679
Mouse monoclonal anti-ACTB (AC-15)	Sigma Aldrich	Cat#: A1978; RRID: AB_476692
Donkey anti-mouse	Jackson ImmunoResearch	Cat#: 715-035-150; RRID: AB_2340770
Donkey anti-goat	Jackson ImmunoResearch	Cat#: 705-035-147; RRID: AB_2313587
Donkey anti-rabbit	Jackson ImmunoResearch	Cat#: 711-035-152; RRID: AB_10015282

REAGENT or RESOURCE	SOURCE	IDENTIFIER
APC anti-CD235a, clone HIR2	eBioscience	Cat#: 17-9987-42; RRID: AB_2043823
Pacific Blue anti-CD41a, clone HIP8	BioLegend	Cat#: 303714; RRID: AB_10696421
Pacific Blue anti-CD11b, clone ICRF44	BioLegend	Cat#: 301315; RRID: AB_493015
FITC anti-CD41a, clone HIP8	eBioscience	Cat#: 11-0419-42; RRID: AB_10718234
FITC anti-CD11b, clone ICRF44	BioLegend	Cat#: 301330; RRID: AB_2561703
Propidium Iodide	eBioscience	Cat#: 00-6990-50
APC Annexin V	BD Pharmingen	Cat#: 550474
Alexa Fluor 488 anti-CD34, clone 581	BioLegend	Cat#: 343518; RRID: AB_1937203
Brilliant-Violet 421 anti-CD38, clone HB-7	BioLegend	Cat#: 356618; RRID: AB_2566231
PE anti-CD71, clone OKT9	eBioscience	Cat#: 12-0719-42; RRID: AB_10717077
FITC anti-CD235a, clone HIR2	BioLegend	Cat#: 306610; RRID: AB_756046
APC anti-TER-119, clone TER-119	eBioscience	Cat#: 17-5921-81; RRID: AB_469472
Rabbit monoclonal anti-GATA1, clone EP2819Y	Abcam	Cat#: ab76121; RRID: AB_1310256
Rabbit monoclonal IgG isotype, clone EPR25A	Abcam	Cat#: ab172730; RRID: AB_2687931
Alexa Fluor 647 Goat polyclonal anti-rabbit IgG (H+L)	Jackson ImmunoResearch	Cat#: 111-605-003; RRID: AB_2338072
Chemicals, Peptides, and Recombinant Proteins		
Dulbecco's Modified Eagle Medium-High Glucose (DMEM)	GIBCO	Cat#: 11965-118
Iscove's Modified Dulbecco's Medium (IMDM)	GIBCO	Cat#: 12440-061
Roswell Park Memorial Institute Medium (RPMI) 1640	GIBCO	Cat#: 11875-119
Fetal Bovine Serum (FBS)	Atlanta Biologicals	Cat#: S11150
Human Holo-Transferrin	Sigma Aldrich	Cat#: T0665-1G
Penicillin-Streptomycin	GIBCO	Cat#: 15140-122
Human Serum, Type AB	Atlanta Biologicals	Cat#: S40110
Human Plasma, Type Ab	Blood Bank at Boston Children's Hospital	N/A

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Humulin R (Insulin)	Lilly	NDC 0002-8215-01
Heparin	Hospira	NDC 00409-2720-01
Epogen (recombinant erythropoietin)	Amgen	NDC 55513-267-10
Recombinant human stem cell factor (SCF)	PeproTech	Cat#: 300-07
Recombinant human interleukin-3 (IL3)	PeproTech	Cat#: 200-03
Opti-MEM	GIBCO	Cat#: 31985-062
StemSpan SFEM II medium	STEMCELL Technologies	Cat#: 09655
StemSpan CC100	STEMCELL Technologies	Cat#: 02690
1-Thioglycerol	Sigma Aldrich	Cat#: M6145
4X Laemmli Sample Buffer	Bio-Rad	Cat#: 161-0747
FuGENE 6 Transfection Reagent	Promega	Cat#: E2691
Dimethyl-sulfoxide (DMSO)	Sigma Aldrich	Cat#: D2438
Cycloheximide	Sigma Aldrich	Cat#: C7698
Polybrene Infection/Transfection reagent	Millipore	Cat#: TR-1003-G
RNasin Plus RNase Inhibitor	Promega	Cat#: N2615
SUPERase IN RNase Inhibitor	Ambion	Cat#: AM2696
cOmplete, Mini, EDTA-free Protease Inhibitor Cocktail	Sigma Aldrich	Cat#: 11836170001
Protease Inhibitor Set	G-Biosciences	Cat#: 786-207
RNase I	Ambion	Cat#: AM2294
Trichloroacetic acid	Sigma Aldrich	Cat#: T9159
Sodium deoxycholate	Sigma Aldrich	Cat#: 30970
RNA Polymerase I Inhibitor II, CX-5461	Millipore	Cat#: 509265
Critical Commercial Assays		
QuikChange site-directed mutagenesis Kit	Agilent Technologies	Cat#: 200518
RNeasy Plus Mini Kit	Qiagen	Cat#: 74134
iScript cDNA Synthesis Kit	Bio-Rad	Cat#: 1708891
iQ SYBR Green Supermix	Bio-Rad	Cat#: 1708882
4-20% Mini-PROTEAN TGX Precast Protein Gels, 12 well	Bio-Rad	Cat#: 4561095
Clarity Western ECL Substrate	Bio-Rad	Cat#: 1705060

REAGENT or RESOURCE	SOURCE	IDENTIFIER
RIPA Lysis Buffer System	Santa Cruz Biotechnology	Cat#: sc-24948A
PARIS Kit	Ambion	Cat#: AM1921
Transcription Factor Buffer Set	BD Pharmingen	Cat#: 562574
Direct-zol RNA MiniPrep Plus w/TRI Reagent Kit	Zymo Research	Cat#: R2071
NEBNext Poly(A) mRNA Magnetic Isolation Module	New England Biolabs	Cat#: E7490
Truseq Ribo Profile (Mammalian) Kit	Illumina	Cat#: RPHMR12126
Ribo-Zero Gold rRNA Removal Kit	Illumina	Cat#: MRZG126
illustra MicroSpin S-400 HR Columns	GE Healthcare Life Sciences	Cat#: 27-5140-01
Zero Blunt TOPO PCR Cloning Kit	invitrogen	Cat#: 450031
Deposited Data		
Whole-exome sequencing data	https://www.ncbi.nlm.nih.gov/gap	dbGAP accession: phs000474.v2.p1
Raw mass spectrometry data	This study	MassIVE: MSV000080283
RNA-seq and ribosome profiling data	This study	GEO: GSE89183
Experimental Models: Cell Lines		
Human CD34 ⁺ hematopoietic stem and progenitor cells, adult	Fred Hutchinson Cancer Research Center	N/A
Human CD34 ⁺ hematopoietic stem and progenitor cells, adult	Department of Hematology/Oncology Flow Cytometry Research Facility at Boston Children's Hospital	N/A
K562 cells	ATCC	Cat#: CCL-243
G1E cells	Weiss et al., 1997	N/A
Experimental Models: Strains		
Yeast: <i>P_{GAL1}-TSR2</i>	Schutz et al., 2014	N/A
Sequence Based Reagents		
shTSR2-1_TRCN0000172642; CCGGGAGGTCACAGCTACGAAATGATCTCGAGATCAITTCGTAGCTGTGACCTCTTTTTTG	Sigma Aldrich	N/A
shTSR2-2_TRCN0000344162; CCGGAGGATTACTTCATGCGCAATGCTCGAGCATTGCGCATGAAGTAATCCTTTTTTG	Sigma Aldrich	N/A
shRPS19-1_TRCN0000074913; CCGGCTACGATGAGAACTGGTTCTACTCGAGTAGAACCCAGTTCTCATCGTAGTTTTTG	Sigma Aldrich	N/A
shRPS19-2_TRCN0000074916; CCGGGCTTGTCTCCCTACGATGAGAACTCGAGTTCTCATCGTAGGGAGCAAGCTTTTTG	Sigma Aldrich	N/A
shRPL5-1_TRCN0000074994; CCGGGTTTGTGTGACAAACAGAGATCTCGAGATCTCTGTTTGTACACGAACTTTTTG	Sigma Aldrich	N/A
shRPL5-2_TRCN0000074997; CCGGCCCTCACAGTACCACAAACGATTCTCGAGAAATCGTTGGTACTGTGAGGGTTTTTG	Sigma Aldrich	N/A

REAGENT or RESOURCE	SOURCE	IDENTIFIER
shRPS24-1_TRCN0000117550: CCGGGCCAAAGAACAGAATGAAGAAACTCGAGTTTCTTCATTTCTTGGCGTTTTTG	Sigma Aldrich	N/A
shRPS24-2_TRCN0000117551: CCGGGATTTATGATTTCCCTGGATTACTCGAGTAATCCAGGGAATCATAAATCTTTTTG	Sigma Aldrich	N/A
shRPL11-1_TRCN0000117712: CCGGGGGGAGTATGAGTTAAGAACTCGAGTTTCTTAACATCATACTCCCGCTTTTTG	Sigma Aldrich	N/A
shRPL11-2_TRCN0000117713: CCGGGCCGAAACTCTGTCTCAACATCTCGAGATGTTGACAGAGTTTGGCGGTTTTTG	Sigma Aldrich	N/A
See Table S6 for all primers used for RT-qPCR.	This study	N/A
See Table S5 for cloned 5' UTR and GATA1 coding sequences.	This study	N/A
Recombinant DNA		
pRS425- <i>hTSR2</i>	Schutz et al., 2014	N/A
pRS425- <i>hTsr2E64G</i>	This study	N/A
HMD-GATA1	Ludwig et al., 2014	N/A
Software and Algorithms		
Image Lab Version 5.2.1	Bio-Rad	http://www.bio-rad.com/en-cn/product/image-lab-software
FlowJo 10.0.7	FlowJo	https://www.flowjo.com/solutions/flowjo
GraphPad Prism 7	Graphpad Software Inc	https://www.graphpad.com/scientific-software/prism/
R version 3.2	The R Foundation	https://www.r-project.org
ExAC	Lek et al., 2016	http://exac.broadinstitute.org
Picard tools	Broad Institute	https://broadinstitute.github.io/picard/
Spectrum Mill MS Proteomics Workbench v6.0 pre-release software package	Agilent Technologies	http://proteomics.broadinstitute.org
FastQC	Babraham Bioinformatics	http://www.bioinformatics.babraham.ac.uk/projects/fastqc
CellProfiler	Carpenter et al., 2006	http://cellprofiler.org